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ABSTRACT 
 The main etiologies of dementia, a neurodegenerative disease, consist of: 
Alzheimer’s Disease (AD), Vascular Dementia (VD), Frontotemporal Lobar Dementia 
(FTD), and Lewy Body Dementia (LBD). AD the most common form of dementia is 
the sixth leading cause of death in the US, where currently 5.3 million Americans are 
diagnosed with Late-Onset and 95% of cases are 65 years and older. Early-Onset 
represents the remaining 5% of cases where ages at diagnosis is younger than 65 
years. AD is characterized by a progressive loss of neurons with impact on patient 
cognition, function, and behavior.  
 The 2015 Alzheimer’s Association Report estimated direct and indirect costs of 
AD and other dementias will reach $226 billion with an expected five-fold increase to 
$1.1 trillion by the year 2050. With no treatment available that stops, or slows down 
progression of the disease places the cost estimates of AD and dementia among the 
most expensive chronic diseases. 
 The next generation of AD medications being investigated will target 
progression of the disease. Disease-modifying medications (DMMs) are being 
developed with a mechanism of action directed towards the main hallmarks found in 
AD patients: the amyloid-beta (Aβ) plaques, and the tau tangles. Tolfenamic acid, a 
non-steroidal anti-inflammatory (NSAID) drug, is being repurposed in the US as a 
DMM for AD treatment; human clinical trials still pending. Aducanumab, a 
monoclonal antibody, binds Aβ and increases its clearance; Phase III human clinical 
trials are in progress. DMMs are anticipated to improve cognition, function and 
behavior. 
  
The objectives, hypotheses, methods and results of this dissertation follow the 
manuscript format, and are three fold: 
 Manuscript 1: The objective was to estimate cost-effectiveness of novel 
disease-modifying medication (DMM) compared to standard medication currently 
used in the treatment of Alzheimer’s disease. The hypothesis was that the DMM 
option will show a favorable cost-effectiveness when compared to standard care. 
Using a Markov Model with a study population comprised of a hypothetical 1000 
patients, 65 years and older, we evaluated quality life years (QALYs) gained by the 
new DMM and an appropriate price to develop a cost-effectiveness framework for the 
new product. In the Markov model we were able to determine an increase in QALYs 
when compared to standard of care with a cost value for DMM much higher than 
current standard care while still showing cost-effectiveness as a new treatment option. 
 Manuscript 2: The objective was to determine affordability to payer’s budget 
i.e. insurance or hospital upon the introduction of the new cost-effective disease-
modifying medication (DMM) class in treatment of Alzheimer’s disease. The 
hypothesis was that the introduction of DMM will have minimal budgetary changes to 
direct costs incurred by payers. Using a 1-year budget impact analysis, a prospective 
short-term analysis was conducted using Optum Clinformatics™ Data Mart (January 
2010-Decemeber 2012), a large national insurer database with administrative health 
claims information, with a study population of patients 65 years and older. Two 
scenarios are to be compared: current mix treatment costs of medications used in 
Alzheimer’s versus a new mix treatment cost that included the addition of DMM to 
current mix treatment. The difference in total payer cost of the two scenarios 
  
represents the budget impact of the new therapy implementation, allowing us to 
predicate future cost of new treatment mix. The study estimated a total per-member-
per-month (PMPM) treatment cost pre- and post- introduction of DMM that would be 
affordable to payer’s and recommended to be added to formulary. 
 Manuscript 3: The objective was to describe prevalence, incidence, and direct 
total cost predictors associated with Early-Onset Dementia (EOD) and its etiologies. 
The hypothesis was that Alzheimer’s disease would be main predicator of overall 
EOD direct cost.  We conducted a retrospective cohort study using Optum 
Clinformatics™ Data Mart (January 2010-Decemeber 2012), a large national insurer 
database with administrative health claims information, with a study population of 
patients 21-64 years and older. Total cost components include: physician visits, 
hospital visits, nursing home care, and prescription drugs associated with EOD 
treatment. Using a Generalized Linear Model (GLM) to assess the relationships 
between total cost and the covariates of interest, we identified age, geographical 
regions, EOD subtypes, and comorbidities as total cost predictors of EOD.  
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PREFACE  
 
 This dissertation is written in the manuscript format, and is comprised of three 
manuscripts, which evaluated (1) cost-effectiveness of new novel disease-modifying 
medications in Alzheimer’s disease, (2) the affordability to payers of said new novel 
medications, (3) the direct cost predicators in Early-Onset Dementia.  
 viii 
 
TABLE OF CONTENTS  
 
ABSTRACT…………………………………………………………ii 
ACKNOWLEDGMENTS…………………………………………...v 
PREFACE……………………………………………………………vi 
TABLE OF CONTENTS……………………………………………vii 
LIST OF TABLE AND FIGURES………………………………….viii 
 MANUSCRIPT 1…………………………………………………...1 
1.1 ABSTRACT……………………………………………………..2 
1.2 INTRODUCTION……………………………………………….3 
1.3 METHODS………………………………………………………4 
1.4 RESULTS………………………………………………………..9 
1.5 DISCUSSION…………………………………………………...10 
1.6 LIMITATIONS…………………………………………………..13 
1.7 CONCLUSION………………………………………………...13 
1.8 REFERENCES…………………………………………………….15 
 MANUSCRIPT 2…………………………………………………….34 
2.1 ABSTRACT………………………………………………………35 
2.2 INTRODUCTION………………………………………………..36 
2.3 METHODS……………………………………………………….37 
2.4 RESULTS…………………………………………………………41 
2.5 DISCUSSION…………………………………………………….44 
2.6 LIMITATIONS……………………………………………………46 
 ix 
 
2.7 CONCLUSION………………………………………………….46 
2.8 REFERENCES……………………………………………………...48 
 MANUSCRIPT 3……………………………………………………..57 
3.1 ABSTRACT………………………………………………………..58 
3.2 INTRODUCTION………………………………………………….58 
3.3 METHODS…………………………………………………………59 
3.4 RESULTS…………………………………………………………..63 
3.5 DISCUSSION………………………………………………………70 
3.6 LIMITATIONS……………………………………………………..73 
3.7 CONCLUSION…………………………………………………...74 
3.8 REFERENCES……………………………………………………….75 
 x 
 
LIST OF TABLES AND FIGURES  
 
TABLES AND FIGURES       PAGE  
Manuscript 1 
Figure 1. Model Framework………………………………………………..23 
Figure 2. Schematic Representation of Markov model………………….....24 
Table 1. Incremental Cost Effectiveness Ratios (ICERs)…………………..25 
Figure 3. Scatterplot DMM compared to SC……………………………….26 
Figure 4. Scatterplot DMM against Willingness-to-Pay (WTP)…………...27 
Figure 5. Cost-Effectiveness (CE) Acceptability Curve……………………28 
Table 2. Sensitivity Analyses Values……………………………………….29 
Figure 6. Tornado Diagram of Net Monetary Benefits…………………….30 
Appendix A. Decision Model Inputs………………………………………31 
Manuscript 2 
Figure 1. Budget Impact Flowchart……………………………………….52 
Table 1. Unit Costs Before and After Introduction of DMM……………..53 
Table 2. Total Budget Impact……………………………………………...54 
Table 3. Sensitivity Analyses………………………………………………55 
Figure 2. Tornado Diagram Per-Member-Per-Month (PMPM)……………56 
Manuscript 3 
Figure 1. Population Flowchart……………………………………………79 
Table 1. Sample Frequency and Demographics…………………………...80 
Table 2. Descriptive Statistics Early-Onset Dementia Subtypes…………..81 
 xi 
 
Table 3. Descriptive Statistics Care Settings in Dementia Patients…………82 
Table 4. Mean and Total Costs of Care Settings…………………………….83 
Table 5. Descriptive Statistics of Total Mean Costs Care Settings………….84 
Table 6. Generalized Linear Model Predicators of Total Direct Cost……….85 
Table 7. Mean Cost of Predictors compared to Total Mean Cost……………86 
Figure 2. Cost of Predictors during 12-month Time Period…………………87 
Appendix A. ICD-9 Medical Codes Early-Onset Dementia………………...88 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1 
 
Manuscript 1 
Title: Cost-Effectiveness of Disease-Modifying Medication in Alzheimer’s Disease 
Rami Beiram1, Stephen Kogut1, Natallia Katenka3, Paul Larrat1, Nasser Zawia2,4,5 
1. University of Rhode Island, Department of Pharmacy Practice, College of 
Pharmacy, Kingston, RI 
2. University of Rhode Island, Department of Pharmaceutical Sciences, College of 
Pharmacy, Kingston, RI 
3. University of Rhode Island, Department of Computer Sciences and Statistics, 
College of Arts and Sciences, Kingston, RI 
4. Interdisciplinary Neuroscience Program, University of Rhode Island, Kingston, RI 
5. George and Ann Ryan Institute for Neuroscience, University of Rhode Island, 
Kingston, RI 
Corresponding Author: Rami Beiram, College of Pharmacy University of Rhode 
Island, 7 Greenhouse Road Suite 266B, Kingston, RI, email: ramibeiram@my.uri.edu 
Funding: Unfunded 
Keywords: Alzheimer’s, disease modifying, cost-effectiveness  
Target Journal: Alzheimer’s & Dementia: The Journal of the Alzheimer’s 
Association  
Format: Short-form paper 
Publication Status: Being prepared for publication in Alzheimer’s & Dementia: The 
Journal of the Alzheimer’s Association  
 
 
 2 
 
1.1 Abstract 
 Our purpose was to estimate the cost-effectiveness of novel disease-modifying 
medication (DMM) in patients with Alzheimer’s disease. A 20 year Markov decision-
analysis model was developed using data from previous studies and databases to 
measure lifetime costs and quality-adjusted life years of DMM compared with current 
standard of care drug therapy. The modeled population was a hypothetical cohort of 55 
year-old patients assigned to the initial Mild Cognitive Impairment (MCI) health state 
in our Alzheimer’s disease model. Health states and progression were defined 
according to the Clinical Dementia Rating Scale (CDR). Patient movement between 
the health states was simulated using transition probabilities derived from published 
sources. The willingness-to-pay threshold was $100,000/quality-adjusted life-year 
gained. 
In the base case, costs for the proposed DMM were $22,000 (SD=$5,000) producing a 
quality-adjusted life years (QALY) estimate at 8.97 (SD=3.50), while the standard of 
care treatment yielded 7.24 QALYs (SD=3.38), having an incremental cost 
effectiveness ratio of $89,222/QALY. In the Monte Carlo probabilistic sensitivity 
analysis the DMM option was cost-effective in 92% of the simulations versus 8% of 
the simulations for the standard of care option. 
The cost-effectiveness of novel DMM in Alzheimer’s patients will depend on 
medication pricing and prolonging time spent in the community against early entry to 
nursing home care. 
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1.2 Introduction 
 Alzheimer’s disease (AD) affects 5.3 million Americans with 95% of patients 
being 65 years or older, two-thirds being female, and with early symptoms showing 5 
to 10 years prior to official diagnosis.1-3 The prevalence of AD is projected to increase 
by 40% in the next 10 years reaching an estimated 14 million patients by the year 
2050.1-3  The incidence of AD increases with age and doubles every 5 years after the 
age of 65.1-4 In 2015 a projected 700,000 people aged 65 or older will have AD as 
cause of death, and although deaths from other major chronic diseases (e.g. HIV) have 
experienced drastic declines it was reported that between 2000-2012 there was a 68% 
increase in cause of death attributed to AD.5,6 The most common cause of death in 
patients with AD is pneumonia.5,6 
 The 2015 Alzheimer’s Association report estimated direct and indirect costs of 
AD and other dementias will reach $226 billion with an expected five-fold increase to 
$1.1 trillion by the year 2050. These estimates place AD and dementia as one of the 
most expensive chronic diseases. Current AD medication cost to payers range between 
$2500 and $3500 annually.7,8 
  AD progression is characterized by the accumulation of amyloid-beta (Aβ) 
plaques and tau tangles leading to neuronal death and loss.9-11 The amyloid precursor 
protein (APP) is cleaved via enzymes into the Aβ peptides which then aggregate, 
deposit into plaques, and initiate the pathology of AD.9-11 In addition to the Aβ 
plaques tau protein is hyperphosphorylated resulting in aggregation and tau tangle 
formations initiating AD pathology.12-14 These processes are the leading causes of 
decline in cognitive function, behavior, and performance of daily activities in patients 
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with AD.12-14 The mechanism of action of current AD medications do not target either 
of the previous mentioned triggers of AD development and progression.8,15,16 
 The next generation of AD medications being investigated will target 
progression of the disease.15-17 Disease-modifying medications (DMMs) are being 
developed with a mechanism of action directed towards the main hallmarks found in 
AD patients: the amyloid-beta (Aβ) plaques, and the tau tangles.15,16 Tolfenamic acid, 
a non-steroidal anti-inflammatory (NSAID) drug, is being repurposed in the US as a 
DMM for AD treatment; human clinical trials still pending.15,16 Monoclonal antibody 
drug class, e.g. Aducanumab  along with other anti-Aβ trial drugs, target Aβ and 
increases its clearance; Phase III human clinical trials are in progress for some of these 
new drug therapies.17-19 Majority of these new therapies will be targeting the early 
mild stages of AD, anticipating improvement in cognition, function and behavior.17-19 
Early detection of AD and providing DMM therapy has potential of limiting AD 
progression, spending more time in the earlier less severe and costly stages of disease 
and increasing time in the community.20,21 
 Predicting the efficacy of novel DMM for AD will exceed current treatment 
options, certainly these medications will be priced at a premium. We assessed the 
value of DMM by conducting a cost-effectiveness analysis. We used Markov 
modeling to simulate the anticipated states of disease progression, and model patients 
with AD transitioning through the different health states predicting clinical outcome 
and cost of DMM therapy. 
 1.3 Methods 
 This study design was a Markov model utilizing published clinical data and 
 5 
 
registry databases as primary data source for: cost, utility values, transition 
probabilities, and medication efficacy converted to relative risk reduction.  
 The study population was comprised of a hypothetical cohort of patients, 55 
years-old, assigned to the initial Mild Cognitive Impairment (MCI) health state of the 
Markov model. Patient movement between the health states was simulated using 
transition probabilities reflecting rates of clinical progression, assigning cost to each 
health state..20-23 (Figure 2) 
 The study’s model was built on a set of specific health states in which a patient 
transitioned through while occupying only one health state at any given time.24-26 The 
model investigated the transitions through several time specified cycles where patients 
entered, stayed, or exited the health state; each health state cycle lasting for 1 year and 
over a 20 year life span of the entire model.24-26 Transition probabilities determined the 
movement among the health states between the two arms of our model,  
DMM vs Standard of Care, as informed by observed rates of disease progression for 
patients treated with currently available medications, as determined in clinical and 
epidemiologic research.24-26 Costs and utility values were assigned to each health state, 
calculated at each cycle, and then aggregated to estimate cost-effectiveness of each 
option. Incremental Cost-Effectiveness Ratios (ICERs) for both the DMM and 
Standard of Care were used for comparison. The DMM arm of the model represents 
any of the current novel proposed DMMs that are in clinical trials, while our Standard 
of Care arm represents the available Alzheimer’s medication therapy available, 
currently marketed in the U.S.27,28 e.g. Donepezil and Memantine. 
 As defined by the National Institute on Aging, of the US Department of Health 
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and Human Services, characterizations of AD progression; our model uses five 
distinctive health states: MCI, mild AD, moderate AD, severe AD, and death.20-22,29 All 
five health states were defined using the Clinical Dementia Rating (CDR) Scale.20,21,29 
The CDR Scale is a universal measure for patient cognitive function determined by 
assigning scores to questions covering six fields: memory, orientation, judgement & 
problem solving, home & hobbies, community affairs, and personal care.30 CDR 
scores range from a minimum of 0 to a maximum of 3, and are categorized in our 
study as follows: 0.5 (MCI) 1 (mild AD), 2 (moderate AD), and 3 (severe AD).22,30-32 
Scores were calculated from the Consortium to Establish a Registry for Alzheimer’s 
disease (CERAD) database, and used in prior studies.30,31 The transition probabilities, 
utility values, and cost analysis studies, from which we extracted our input parameters, 
used CDR as their scale to define the AD health states.22,31-33  
 The model began with a hypothetical 1000 patient population distribution 
assigned to the initial MCI health state and simulates patient movement through the 
progressive states using transition probabilities.20-22,34 The transition probabilities 
defined the rate of progression through the health states; for example a patient in 
moderate AD can remain in that same state, move to severe state, or enter the 
absorbing state of death which they do not exit.20-22,34 No movement backwards to a 
less severe state was permitted. 
 The simulated patient cohort was assigned transition probabilities based on 
therapy received: DMM or Standard of Care. Completion of each individual cycle 
produced an estimated cost and quality-adjusted life years (QALY) gained, for 
treatment comparisons. The measure effect was in incremental cost/QALY gained, 
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assessing the influence of DMM treatment on AD progression as compared to 
Standard of Care.  
 Model parameter inputs included: costs (medications, outpatient visits, 
inpatient stays, and long-term facility e.g. nursing home); utility values used for 
quality-adjusted life years (QALY) gained calculation, transition probabilities, and 
relative risk (RR) representing DMM treatment effect. With most of the DMM under 
consideration still undergoing clinical trials we made a RR assumption value of 0.5, 
predicting that DMM will be at least as effective as Donepezil where the RR of 
transitioning from mild to moderate AD was 50% less in treatment group when 
compared to placebo group.35 We assumped that DMM will in fact impact progression 
of the disease unlike current treatments available.17,36 The RR value was applied to 
produce new transition probabilities, in the DMM arm of the model, to simulate the 
impact of new therapy. From the previous unsuccessful DMM monoclonal antibody 
clinical trials, and the current ongoing trials the population target is those in the early 
stages of Alzheimer’s that will benefit most from DMM therapy i.e. MCI or mild 
Alzheimer’s patients17-19,36. We applied the RR to transition probabilities, in DMM 
arm, to health states of MCI and Mild AD, reducing transition probabilities from the 
earlier states to the more severe states. Published literature was primary source for: 
cost, utility values, transition probabilities, and RR. Micromedex Redbook database 
was the source of price for Standard of Care medications, using Average Wholesale 
Price (AWP) as our benchmark. (Table 1) 
 To predict DMM future market cost we considered Multiple Sclerosis (MS)-a 
neurodegenerative illness which uses disease-modifying medication type therapies. 
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The price of new therapies in MS, which are mainly of the monoclonal drug class, are 
usually 5 times higher than current medication treatments.37 Average cost of 
monoclonal antibodies currently on the market, in other disease states, were also 
considered to aid in the assumption as to the cost of these proposed new therapies in 
AD. Using this rationale the study assumed a cost of $22,000 per year, included in 
which was cost of physician visit where administration of medication would occur.  
Descriptive statistics were presented for AD costs, while the simulation following 
patient movements between the health states calculates expected costs and quality-
adjusted life years (QALY) gained. This was carried out for each specific health state 
at each cycle the model goes through producing an incremental cost per QALY for 
each state, weighted by the proportion of patients in the health state before totaling 
across all cycles.38-40 The process described uses a Monte Carlo Simulation. The 
Monte Carlo simulation allows the above mentioned process to be repeated 1000 times 
through the time horizon of the entire model.38-40 The incremental cost/QALY 
produced was compared to the Willingness-to-Pay/QALY ($100,000 per QALY) to 
determine cost-effectiveness of DMM treatment.38-41  
 Probabilistic sensitivity analysis (PSA) was used to reflect input parameters’ 
uncertainty.38,42,43 Input parameters’ distributions were assigned as follows: beta 
distribution for utilities, gamma distribution for DMM cost, and log-normal applied to 
the Relative Risk and transition probabilities.40,42   
 PSA in the Monte Carlo simulation chose a random value from each of the 
input parameters from the specified distribution assigned for each model iteration.40,42 
Each single model run generated a single incremental cost-effectiveness ratio (ICER) 
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value, and with repeating the process 1000 times produced a distribution of ICERs. 
The resulting ICERs with confidence intervals was plotted on a cost-effectiveness 
plane graph. Given the time value of costs and QALYs, a dollar and QALY is worth 
more today than it would be tomorrow, a standard discount rate of 3% to present value 
of future costs and QALYs was incorporated.40,42 Model building and all statistical 
analysis were performed using TreeAge Software, Inc. version Pro 2016 (Williamston, 
MA). 
1.4 Results 
 Diagram representation of the Markov model (Figure 2) illustrates that all 
patients start at 55 years-old with Mild Cognitive Impairment (MCI). Patients’ cycle 
between health states until death occurs or the 20-year model time horizon was 
reached. The length of each cycle was 1 year. Illustrated in the diagram was the 
decision node (square), chance nodes (circles) directed by transition probabilities, 
Markov nodes (circle with ‘M’), and terminal nodes (triangles). Markov branch for the 
standard of care (SC) therapy was identical to the disease-modifying medication 
(DMM) branch shown.  
In the base case (Table 2), quality-adjusted life expectancy (QALY) for our disease-
modifying medication (DMM) was 8.98 (SD=3.32) versus the standard of care (SC) 
7.41 (SD=3.28). When compared to SC, DMM produced an additional 1.57 QALY at a 
cost of $154,852, estimating an incremental cost-effectiveness ratio (ICER) of $89,222 
per QALY, and below our established willingness-to-pay (WTP) threshold of $100,000 
per QALY. 
 One-way sensitivity analyses were conducted for our model parameters to 
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determine the variables with most impact on our results. Key input parameters were 
varied one input at a time while holding other constant at their base-estimates.  
 Sensitivity analyses was conducted on costs, probabilities, and utilities.  
A tornado diagram (Figure 6) illustrating the cost variables in descending order of 
influence was developed. The horizontal bars in the diagram represent net monetary 
benefit values expected from the range of values evaluated for each of our influential 
model parameters. The vertical black line on the bars represents a change in the DMM 
arm when the variable starts producing net monetary benefit. Parameters with most 
impact on the model were costs: price of the DMM therapy; probabilities: transition 
probability from Mild Cognitive Impairment (MCI) to Mild AD; utilities: utility value 
for MCI, and the relative risk reduction (RR) parameter.  
The Monte Carlo Probabilistic Sensitivity Analysis (PSA) incorporated both intra-
individual and parameter uncertainty respectively produced results presented in Table 
2. Using the WTP of $100,000 our DMM produced an ICER of $89,812/QALY with 
92% of the iterations showing cost-effectiveness when compared to 8% in SC. (Figure 
4). The cost-effectiveness acceptability (CEA) curve also illustrates the probability 
that DMM therapy will be cost-effective at varying WTP thresholds for a patient 
(Figure 5). 
Table 3 presents the sensitivity analyses for the ICERs associated when varying 
parameter assumptions. When DMM cost was considered we estimated an ICER of 
$53,627/QALY and $128,549/QALY for 10% decrease and 10% increase in the price 
of the drug therapy, respectively. The results shown in other parameters were sensitive 
to varying the assumptions of their values. Varying the probability of disease 
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progression (MCI to Mild AD) estimated ICERs of $76,695/QALY and 
$106,645/QALY for 10% decrease and 10% increase, respectively. Utility weight for 
MCI had ICERs of $105,651/QALY and $81,284/QALY for 10% decrease and 10% 
increase, respectively. 
1.5 Discussion 
 Our study demonstrated that a disease-modifying medication (DMM) delaying 
the cognitive decline, increasing time spent in the less severe and costly health states 
of Alzheimer’s disease (AD) can possibly be cost-effective when compared to current 
medication therapies. This study can provide a framework or working design that 
estimates the assumed and possible effect of these newly proposed novel DMM that 
are currently in clinical trial pipelines. The study used published data to build the 
decision, but with deficiencies in direct evidence on DMM effects or possible costs 
associated with the new therapy. Currently there are several anti-amyloid beta 
monoclonal antibodies in the pipeline of companies, with some of the more recent 
trials reaching Phase III but unfortunately not being able to show progress.17-19,36,44 
Aducanumab, a monoclonal antibody, is currently the most promising of the pipeline 
products showing credible progress in Phase III trials in the early less several AD 
health states18,19 i.e. MCI and Mild AD. Given that no such DMM is on the market yet 
we had to make an assumption of expected price, using sensitivity analysis to 
determine with all our input parameters and WTP level that a price as high as $23,189 
per year will maintain cost-effectiveness favorability of new therapy. In similar 
manner, we estimated that a relative risk reduction of 0.546 would maintain cost-
effectiveness for new therapy. Despite these uncertainties our model framework can 
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still provide hypothetical information on what to expect from DMM, and the model 
inputs can be updated once more of the clinical trial results become available and 
published.  Additional uncertainty highlighted in our model were the direct cost inputs 
of the various health states of AD i.e. mild or moderate, community or nursing home. 
Rice et al. 1994 was one of the very few studies available that broke down the costs of 
AD by level of severity in a population in North California. Similarly, two review 
studies by Mauskopf et al. (2010 and 2011), estimating the cost of AD in the U.S. as 
well as the association of cost with disease severity provided a source of cost 
information for our model to make up for the lack of current cost studies in AD.45,46 
The use of a claims database of a U.S. population might provide a solution and useful 
information in AD cost studies, but patients are not diagnosed based on disease 
severity and are usually recorded as AD and not as mild AD or moderate AD. The 
severity of disease states might be recorded in the medical record as notes but not 
captured in a database. Hence, a study similar to the Rice et al. 1994 study that 
categorizes patients by disease severity in a healthcare setting and follows them as 
they progress to capture their costs would be ideal way to capture more definite and 
specific costs. 
An aspect of our study to consider is that using DMM patients are expected to spend 
more time in the less severe states spending more time in the community setting, and 
if considering a societal prospective then we would predict a delay in nursing home 
placement and its cost but at the expense of increased unpaid family caregivers to aid 
with the patients.22 Our model focuses primarily of direct cost of care, when the 
biggest factor contributing to the rising cost of AD are the indirect costs; costs 
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associated with unpaid family caregivers, loss of productivity associated with both 
patients and caregivers.22,45 When considering our study using a payer e.g. Insurance 
perspective we should be cautious when trying to generalize it to an insurer or a 
managed care plan. Given the uncertainty in relative risk reduction proposed for these 
DMM still in clinical trials, the utility values based on current AD status which we 
would expect to change with the slowing down of cognitive decline, and the cost 
information based on several older studies we are restrained when interpreting our 
results. 
1.6 Limitations 
 This study provides a look into complexity of trying to model a chronic 
condition such as AD. All the assumptions, inputs, and sensitivity analysis are to be 
considered carefully given the lack of current DMM efficacy, cost, or impact on utility 
values. Our basic assumption was that DMM will work particularly well in the early 
less severe stages of AD, despite the several setbacks in clinical trials during the past 
years but with still compounds being developed in the pipeline. The direct costs our 
study used are dependent on the U.S. health system and might not be generalizable to 
other countries given the wide range of different health insurance systems available. 
The utility values (QALYs) were not validated in any trial using DMM so we have no 
information on how the DMM will affect utility values or how they will change as 
disease progresses. Side effects and their costs are usually part of cost-effectiveness 
calculations, however with DMM still in clinical trial phases we yet to have access to 
such information and being a simulation no such information was added to our model. 
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1.7 Conclusion 
 Our model results, using available data, showed that future disease-modifying 
medications in Alzheimer’s disease may be cost-effective when adopting a 
willingness-to-pay of $100,000, and adding additional quality-of life year gained to 
patients. We conclude that at cost of $23,000 or less and relative risk reduction of 
0.546 or more disease-modifying medications would be cost-effective. Considering 
current evidence and developments of these medications and other interventions, we 
can update and re-evaluate the cost-effectiveness studies for Alzheimer’s disease in the 
future. 
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Figure 1. Model Framework 
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Figure 2. Schematic representation of the Markov model framework of Disease-
Modifying Medication (DMM). Patients cycle between health states until death 
occurs or 20-year model-time horizon is achieved. Decision node (square), chance 
nodes (circles) directed by transition probabilities, Markov nodes (circle with 
“M”), and terminal nodes. Standard of Care (SC) branch is identical to DMM 
branch 
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Table 1. Projected Costs, Quality Adjusted Life Years (QALYs), and Incremental 
Cost Effectiveness Ratios (ICERs) comparing Disease-Modifying Medication 
(DMM) Therapy with current Standard of Care (SC) Therapy  
 
  Base Case 
 
  
        
  Total Cost (SD) QALY (SD) ICER 
        
Standard of Care (SC) $446,918 ($317,108) 7.24 (3.38) …* 
  
   Disease-Modifying 
Medication (DMM) $601,770 ($446,917) 8.97 (3.5) $89,222/QALY 
        
  
Probabilistic Sensitivity 
Analysis (PSA)     
        
  Total Cost (SD) QALY (SD) ICER 
        
Standard of Care (SC) $447,817 ($9,792) 7.46 (0.68) …* 
        
Disease-Modifying 
Medication (DMM) $596,616 ($10,902) 9.11 (0.98) $89,812/QALY 
        
        
ICER indicates incremental cost-effectiveness ratio; 
QALY, quality-adjusted life year; SD, standard deviation     
*SC is the reference 
therapy for ICER 
calculation       
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Figure 3. Scatterplot of Disease-Modifying Medication (DMM) and the Standard 
of Care (SC). Illustrates the Total Cost (y-axis) and Total Quality-Adjusted Life 
Year (QALY) gained (x-axis) during the time-horizon of the model. DMM 
(purple) shows higher QALYs gained at higher Total Cost when compared to SC 
(green) 
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Figure 4. Scatterplot of Disease-Modifying Medication (DMM) versus Standard 
of Care (SC). Showing that with a Willingness-to-Pay (WTP) of $100,000 
(represented by dash line ---) per Quality-Adjusted Life Year (QALY), 92% of 
model iterations are below the WTP threshold and favoring the DMM Therapy 
arm of the Markov model and estimating an additional 1.5 to 1.82 QALY 
through the time-horizon of the model 
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Figure 5. Cost-Effectiveness (CE) Acceptability Curve Represents Probability 
that a Treatment will be CE (percentage iterations (y-axis) for which treatment 
was CE) at varying Willingness-to-Pay Thresholds (x-axis). The amount, in 
dollars, payer willing to pay to pay to achieve an additional quality-adjusted life 
year 
 
 
DMM – Disease-Modifying Medication (blue) 
SC – Standard of Care (orange) 
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Table 2. Sensitivity Analyses 
 
    Incremental Cost Effectiveness Ratio (ICER, $) 
Parameters     
      
Base Case   $89,222  
      
Relative Risk Reduction (Drug Effect)     
  10 % Higher   $87,977  
  10 % Lower   $107,455  
      
DMM cost (Drug Cost)     
  10% Higher   $53,627  
  10% Lower   $128,549  
      
Utility Weight (QALY for MCI)     
  10% Higher   $81,284  
  10% Lower   $105,651  
      
Probability of Disease Progression (MCI to Mild AD)     
  10% Higher   $106,645  
  10% Lower   $76,695  
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Figure 6. Tornado Diagram Represents Net Monetary Benefit (NMB) Values 
Expected from a Range of Values Evaluated for each Variable with Impact on 
the model. The Vertical black line represents the NMB Value that occurs where 
change to our preferred treatment i.e. Disease-Modifying Medication happens for 
the given variable 
 
 
uMCI – Utility Value Mild Cognitive Impairment (MCI) 
cDMM – Cost of Disease-Modifying Medication (DMM) 
RR – Relative Risk (RR) for DMM  
pMCI1toMild1 – Transition Probability of Disease from Mild Cognitive Impairment (MCI) to 
Mild Alzheimer’s  
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APPENDIX A. Decision Model Inputs: probabilities, costs, and utilities for both 
Arms of the Markov Model; Standard of Care (SC) and Disease-Modifying 
Medication (DMM) 
 
Standard of Care (SC)   
Item Estimate Data Source 
Annual Transition Probabilities   
  Stage to Stage   
  MCI to MCI 0.88 33, 50 
  MCI to Mild 0.088 33, 50 
  MCI to Moderate 0.01 33, 50 
  MCI to Severe 0.008 33, 50 
  MCI to Death 0.014 33, 50 
  Mild to Mild 0.79 33, 50 
  Mild to Moderate 0.141 33, 50 
  Mild to Severe 0.023 33, 50 
  Mild to Death 0.046 33, 50 
  Moderate to Moderate 0.777 33, 50 
  Moderate to Severe 0.083 33, 50 
  Moderate to Death 0.14 33, 50 
  Severe to Severe 0.782 33, 50 
  Severe to Death 0.218 33, 50 
*Costs, $   
  By Stage and Setting   
   MCI:   
    Community $8,000  22, 45, 49 
    Nursing Home Not Reported 
   Mild:   
    Community $11,000  22, 45, 49 
    Nursing Home $67,000  22, 45, 49 
   Moderate:   
    Community $14,000  22, 45, 49 
    Nursing Home $73,000  22, 45, 49 
   Severe:   
    Community $23,000  22, 45, 49 
    Nursing Home $78,000  22, 45, 49 
  Other Costs   
   Medications:   
    Donepezil $3,000  AWP 
    Memantine $2,000  AWP 
Quality-of-Life Weights (Utility)   
  By Stage   
   MCI 0.76 47, 48 
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   Mild 0.69 47, 48 
   Moderate 0.53 47, 48 
   Severe 0.38 47, 48 
   
Disease-Modifying Medication (DMM)   
Item Estimate Data Source 
Annual Transition Probabilities   
  Stage to Stage   
  MCI to MCI 0.933 Author 
Calculations† 
  MCI to Mild 0.044 Author 
Calculations† 
  MCI to Moderate 0.005 Author 
Calculations† 
  MCI to Severe 0.004 Author 
Calculations† 
  MCI to Death 0.014  
  Mild to Mild 0.872 Author 
Calculations† 
  Mild to Moderate 0.0705 Author 
Calculations† 
  Mild to Severe 0.0115 Author 
Calculations† 
  Mild to Death 0.046 33, 50 
  Moderate to Moderate 0.777 33, 50 
  Moderate to Severe 0.083 33, 50 
  Moderate to Death 0.14 33, 50 
  Severe to Severe 0.782 33, 50 
  Severe to Death 0.218 33, 50 
*Costs   
  By Stage and Setting   
   MCI:   
    Community $8,000  22, 45, 49 
    Nursing Home Not Reported 
   Mild:   
    Community $11,000 22, 45, 49 
    Nursing Home $67,000 22, 45, 49 
   Moderate: $14,000  22, 45, 49 
    Community $73,000  22, 45, 49 
    Nursing Home   
   Severe: $23,000  22, 45, 49 
    Community $78,000  22, 45, 49 
    Nursing Home   
  Other Costs   
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   Medications:   
    Donepezil $3,000  AWP 
    Memantine $2,000  AWP 
    Disease-Modifying Medication   (DMM) $22,000  Author 
Assumptions‡ 
Quality-of-Life Weights (Utility)   
  By Stage   
   MCI 0.76 47, 48 
   Mild 0.69 47, 48 
   Moderate 0.53 47, 48 
   Severe 0.38 47, 48 
Effect of Disease-Modifying Medication    
   MCI-to-Mild Transition 0.5 Author 
Assumptions‡ 
   MCI-to-Moderate Transition 0.5 Author 
Assumptions‡ 
   MCI-to-Severe Transition 0.5 Author 
Assumptions‡ 
   Mild-to-Moderate Transition 0.5 Author 
Assumptions‡ 
   Mild-to-Severe Transition 0.5 Author 
Assumptions‡ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Costs were inflated and rounded up to estimate 2016 
dollar values 
   
AWP- Average Whole Sale Price. Using Micromedex Red 
Book 
    
† Author Calculations using an assumed relative risk 
reduction of 0.5 
   
‡ Author Assumption using current treatment effectiveness, costs, and proposed 
medications undergoing clinical trials 
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2.1 Abstract 
 A new therapeutic class of disease-modifying medications (DMM) are now 
being developed for the management of Alzheimer’s disease (AD). The objective of 
our study was to estimate the future financial consequences on a U.S. health care plan, 
having a population size of 2.6 million, after the introduction of proposed novel 
DMM. A 1- year budget impact model, estimating percentage of patients on current 
AD medications and quantities filled were measured using the 2010-2012 Optum 
Clinformatics™ Data Mart; a large national insurer database with administrative 
health claims information from a private health plan in the U.S. We identified 436 
patients with an AD diagnosis, and having filled specific AD medications during the 
2012 study period. Total budget costs of before and after the introduction of the 
proposed DMM were estimated in addition to the incremental changes in the per-
member-per-month (PMPM) cost. Sensitivity analyses were performed to evaluate the 
impact of varying percentage of patients receiving AD medications, the price of new 
proposed medication, percentage of patients switching from current therapy to new 
medications, percentage of patients adding the new medication to their current therapy, 
and percentage of new cases utilizing the new medication therapy. The expected 
annual medication budgetary cost for AD medication utilization including the DMM 
was $5,040,748 compared to $1,004,954 cost prior to the including DMM, 
representing a 5-fold increase. The total incremental medication cost was $0.1616 
PMPM, an increase from the $0.0322 PMPM cost before the DMM was introduced. 
Using administrative claims database to estimate AD medication cost and utilization, 
the introduction of novel DMM therapy will have a substantial effect on both the total 
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and PMPM cost for AD medication budget. Given the importance of affordability of 
new treatments to decision and policy-makers greater attention and planning needs to 
be afforded to the expected sizable change predicted to occur with introduction of new 
novel DMM therapy. 
2.2 Introduction 
 Currently there is no cure for Alzheimer’s disease (AD), guidelines by both the 
American College of Physicians and the American Academy of Family Physicians 
divide treatment for AD into 2 medication categories1,2:  Acetylcholinesterase 
Inhibitors (AChEIs) e.g. Donepezil and N-methyl-D-aspartate (NMDA) e.g. 
Memantine. The AChEIs prevent the breakdown of acetylcholine, a neurotransmitter 
required for neuronal function, and help increase levels of the declining 
neurotransmitter due to neuronal loss.1-3 The NMDAs reduce levels of glutamate 
receptor activation and decrease neuronal dysfunction.1-3 The use of these therapeutic 
agents as monotherapies or in combination during various stages of AD improve 
cognition and daily functioning scale score slightly, but do not slow down progression, 
decline in cognition, or cure AD.3-5  
 AD progression is characterized by the accumulation of amyloid-beta (Aβ) 
plaques and tau tangles leading to neuronal death and loss.6,7 These hallmarks, Aβ and 
tau tangles, are the targets of new investigational disease-modifying medication 
(DMM), currently undergoing clinical trials, trying to slow AD progression and reduce 
cognitive decline.4,5,8,9 Monoclonal antibody drug class, e.g. Aducanumab along with 
other anti-Aβ trial drugs, target Aβ and increases its clearance; Phase III human 
clinical trials are in progress for several of these new drug therapies.5,9,10 Majority of 
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these new therapies will be targeting the early mild stages of AD, anticipating 
improvement in cognition, function and behavior.5,9,10 With the efficacy of proposed 
DMM monoclonal anti-body therapy expected to target the underlining causes of AD, 
these DMM are expected to be priced at a premium. Current AD medications, AChEIs 
and NMDAs, cost to payers range between $2500 and above $3500 annually. With 
limited resources, decision makers have to determine the future budgetary impact with 
the addition of new therapies, and judge competing treatments on both clinical and 
cost effectiveness. 
2.3 Methods 
 This study design was a 1-year retrospective before and after budget impact 
analysis used to estimate the medication treatment cost of Alzheimer’s disease (AD) 
before and after the introduction of a proposed disease-modifying medication (DMM). 
Pharmacy claims data from Optum Clinformatics™ Data Mart served as the primary 
data source for estimates of cost and utilization for current AD medications. Optum 
Clinformatics Datamart™, a large national insurer database with administrative health 
claims information for approximately 19 million patients, collected from January 2010 
to December 2012.  
 The study population was comprised of continuously enrolled patients, from 
2010 to 2012, who were 55 years and older with AD diagnosis and had an AD specific 
medication prescription e.g. AChEIs or NMDAs filled during the 2012 year.  
 Population selection was as follows: all continuously enrolled patients who 
were at risk (55 years and older 4,5), with a diagnosis of AD in accordance with the 
International Classification of Disease 9th Edition Clinical Modification [ICD-9-CM] 
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medical codes (AD ICD-9-CM code 331.0). Relevant codes were reviewed and 
selected from the Agency for Healthcare Research and Quality (AHRQ), using the 
Clinical Classification Software (CCS) from the Healthcare Cost and Utilization 
Project (HCUP). The Clinical Classification Software (CCS) for ICD-9-CM is a tool 
on the HCUP website, sponsored by AHRQ, which provides over 14,000 diagnosis 
codes and 3,900 procedure codes.  AD patients who were enrolled during 2012 and 
met the age criterion of 55 years and older, and had AD specific medications filled 
during the 2012 year made up our cohort used for analysis.  
 AD specific medications considered were AChEIs: Aricept (donepezil), Exelon 
(galantamine), Razadyne (rivastigmine), and NMDAs: Memantine. During 2012 
Namenda was only available as brand with the generic (memantine) not entering the 
market until 2014, and the new Namzaric (donepezil/memantine) not available until 
2016. Namenda XR also did not become available till 2014. We expect the price of 
Namenda XR and Namzaric to be comparable to Namenda. The medications collected 
from our database captured all formulations and dosage strengths that were prescribed. 
The current or before addition of DMM mix (2012) of medications were categorized 
as; AChEIs monotherapy, NMDA monotherapy, or AChEIs plus NMDA dual therapy 
and the same categorization was completed for the new or after addition of DMM 
mix.1,3 
 Two scenarios were compared: current mix treatment costs consisted of 
medication costs before DMM available on market, and the new mix treatment after 
following DMM introduction to the market. (Figure 1)  
 Current treatment mix costs was based on the 2014 prices of our Optum 
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Clinformatics™ Data Mart databases as our baseline. The costs for each of our 
medication categories (AChEIs, NMDA, and AChEI+NMDA) represented amount 
charged to the insurer, minus patient coinsurance, copay or patient out of pocket 
payments towards their deductible. Current mix included: total number of 
prescriptions for each medication category, the number of patients utilizing the 
prescriptions, and an estimate mean cost of per prescription along with per patient 
prescription utilization mean for each of our medication category was determined.  
 New treatment mix was developed using 3 assumptions: 2% of newly 
diagnosed AD patients measured as coming into the health plan at the start of the year, 
20% of patients on current treatment category (AChEIs, NMDA, and AChEI+NMDA) 
will switch to the new DMM therapy, and 10% of patients on current treatment 
category (AChEIs, NMDA, AChEI+NMDA) will add the new DMM therapy to their 
current mix. Patients with Cardiac arrhythmias were contraindicated to start, switch, or 
add new DMM monoclonal antibody therapy per the clinical trial results conducted o 
these newer medications.4,10 Patients who switched have their prescriptions and its 
costs subtracted from the new mix total cost and prescription count, replaced with the 
DMM cost and prescription count. Data from current and previous clinical trials on 
proposed monoclonal anti-body DMM therapy proposed a one-time infusion of the 
medication every 4 weeks.4,5,10 Current AD medications, AChEIs and NMDAs, cost to 
payers range between $2500 and above $3500 annually.3,11 To predict DMM future 
market cost we considered Multiple Sclerosis (MS)-a neurodegenerative illness which 
uses disease-modifying medication type therapies. The price of new therapies in MS, 
which are mainly of the monoclonal drug class, are usually 5 times higher than current 
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medication treatments.12 Average cost of monoclonal antibodies currently on the 
market, in other disease states, were also considered to aid in the assumption as to the 
cost of these proposed new therapies in AD. Using this rationale the study assumed a 
cost of $24,000/year or $2,000 for a monthly prescription. We can assume a single 
prescription a month for 12-months of the new DMM therapy to determine the annual 
total cost with a per prescription cost of $2,000 that was previously assumed.  
 New treatment mix costs, after DMM introduction include: the cost of the 
newly diagnosed patients entering the health plan with no current therapy starting 
DMM, cost of current mix that was not lost to patients switching, and cost of patients 
that added the new therapy to their current medications. (Figure 1) The difference in 
total payer cost of the two scenarios (current mix minus new mix) represents the 
budget impact of DMM therapy implementation.13,14 (Figure 1) In addition the study 
estimated the total per-member-per-month (PMPM) AD treatment cost before and 
after introduction of DMM therapy, determined by dividing the total cost by the 
population at risk eligible to receive DMM and dividing result by 12 months13,14. 
 One-way sensitivity analyses were used to evaluate the impact of varying 
parameters on total cost and the PMPM value. In our model the following parameters 
were varied: percentage of AD patients on AD specific medications, price of DMM 
therapy, percentage of new cases utilizing DMM, percentage of patients switching 
from current therapy to DMM, and percentage of patients adding DMM to their 
current therapy. Each parameter was varied from the default value by ±50% for each 
of our parameters to estimate the lowest total cost and PMPM, and the highest total 
cost and PMPM compared to the base-case assumptions. The model was built, and 
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calculations estimated using Microsoft Excel. 
 
2.4 Results 
 The total population at risk for Alzheimer’s disease (AD), in the Optum 
Clinformatics™ Data Mart database, was approximately 2.6 million individuals (55 
years and older). Among them we found 2,203 that had an AD diagnosis and enrolled 
between the 2010-2012 years. Among those individuals a total of 436 patients (20%) 
had AD specific medications filled e.g. Donepezil or Memantine filled during 2012. 
Measuring utilization of AD medications (Table 1) and categorizing them by drug 
class Acetylcholinesterase Inhibitors (AChEIs): Donepezil (Aricept), Galantamine 
(Exelon), Rivastigmine (Razadyne),, and N-Methyl-D-Aspartate (NMDA): 
Memantine (Namenda); patients received a total 5,088 prescriptions (Rx) of AD 
medications. Among those prescriptions 1,526 (30%) Rx in 144 patients were for 
AChEIs monotherapy with an average of 10.6 Rx filled per patient, 585 (11.5%) in 44 
patients were for NMDA monotherapy with an average of 13.3 Rx filled per patient, 
2,976 (58.5%) in 248 patients were for dual therapy of AChEIs plus NMDA with an 
average of 12 Rx filled per patient. Mean costs per Rx for each of the drug class 
categories are presented in Table 1: $147 per Rx filled in AChEIs monotherapy, $271 
per Rx filled in NMDA monotherapy, and $209 per Rx filled in dual therapy of 
AChEIs plus NMDA. Total cost of prescriptions among the various drug classes was 
as follows: AChEIs monotherapy $224,380, NMDA monotherapy $158,589, and dual 
therapy AChEIs plus NMDA $621,984 (Table 2) 
 After introduction of DMM (Table 1), 44 (2%) of our AD cohort (2,203) were 
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considered newly diagnosed in health plan annually during the 2010-2012 years. The 
study assumed switching of patients from current medication treatment to DMM as 
well as adding DMM to current treatment; yielding an additional 88 (20%) patients 
who switched and 45 (10%) that added DMM and bringing total amount of patients 
receiving DMM therapy to 177. With each DMM patient receiving 1 Rx per month the 
number of prescriptions added to the new treatment mix were 2,122 prescriptions, and 
increasing total number of prescriptions to 6,159 ( 21% increase) after the addition of 
DMM and subtracting the cost and number of prescriptions that switched therapy 
(Table 2). We estimated new treatment mix total prescriptions 6,159: DMM 2,122 
(34%), AChEIs monotherapy 1,208 (20%), NMDA monotherapy 461 (7.5%), and dual 
therapy AChEIs plus NMDA 2,368 (38.5%). Total cost of prescriptions among the 
new treatment mix was as follows: DMM $4,243,200, AChEIs monotherapy $177,534 
NMDA monotherapy $125,052, and dual therapy AChEIs plus NMDA $494,961 
(Table 2). Represented in Table 2 are costs of prescriptions before and after addition of 
DMM, included are: total cost, per-member-per-month [PMPM], incremental cost 
with total change. Total cost and PMPM before DMM was $1,004,954 [$0.0322] 
compared to $5,040,748 [$0.1616] after DMM addition, with an incremental cost 
change of $4,035,794 [$0.1294] an increase of 400%. The breakdown of cost by the 
drug categories was as follows: DMM $0 before compared to $4,243,200 after, 
AChEIs monotherapy $224,380 compared to $177,534 after DMM addition with an 
incremental cost decrease of $46,846 (20.8%), NMDA monotherapy $158,589 
compared to $125,052 after DMM addition with an incremental cost decrease of 
$33,537 (21.1%), and dual therapy AChEIs plus NMDA $621,984 compared to 
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$494,961 after DMM addition with an incremental cost decrease of $127,023 (20.4%). 
 Table 3 summarizes the findings from one-way sensitivity analyses in our new 
treatment mix with a total cost of $5,040,748 and a PMPM $0.1616 as our base-case 
assumptions. In our model the following parameters were varied: percentage of AD 
patients on AD specific medications, price of DMM therapy, percentage of new cases 
utilizing DMM, percentage of patients switching from current therapy to DMM, and 
percentage of patients adding DMM to their current therapy. Each parameter was 
varied from the default value by ±50% to estimate the lowest total cost and PMPM, 
and the highest total cost and PMPM. Results were as follows; percentage of patients 
with AD prescriptions: low value with 50% decrease was $3,050,774 [$0.0978] and 
high value $7,030,723 [$0.0.2253], cost of DMM therapy: low value $2,919,148 
[$0.0936] and high value $7,162,348 [$0.2296], percentage of new cases utilizing 
DMM: low value $4,483,828 [$0.1437] and high value $6,101,548 [$0.1956] 
percentage of patients switching current therapy to DMM: low value $4,090,401 
[$0.1311] and high value $5,991,095 [$0.192], percentage of patients adding DMM to 
current therapy: low value $4,510,348 [$0.1446] and high value $5,571,148 [$0.1786].  
 Figure 2 summarizes the PMPM findings of our one-way analyses using a 
tornado diagram, ranking the parameters from most to least influence on our model 
and overall outcome of total cost and PMPM. When the price of DMM was increased 
by 50% the total cost increased by 42% (or by $0.068 PMPM). When percentage of 
patients using AD medications was increased by 50% total cost increased by 39% (or 
by $0.0637 PMPM). When new cases utilizing DMM was increased by 50% the total 
cost increased by 21% (or by $0.034 PMPM). When percentage of patients switching 
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to DMM was increased by 50% the total cost increased by 19% (or by $0.0304 
PMPM). When percentage of patients adding DMM was increased by 50% the total 
cost increased by 10.5% (or by $0.017 PMPM). 
2.5 Discussion 
 Alzheimer’s disease (AD) has become one of the most financially taxing 
chronic diseases on individuals, the health care system, and society.15-18 There is no 
cure or treatment for AD with current available medications not impacting progression 
of disease or slowing down cognitive decline.3,4 Future disease-modifying medications 
(DMM) currently in clinical trials are the focus of the future treatment paradigm of 
AD.4,5,19 In this study, with the perspective of a payer as our focus, we were able to 
suggest that the future introduction of a DMM into a health care plan, or a formulary 
list given that the new therapy is cost-effective will have a substantial increase on the 
budgetary strategy of the health care systems. The overall budget model in our 2.6 
million eligible population, using medication utilization and cost data from the Optum 
Clinformatics™ Data Mart, revealed a budget impact of almost 4-fold, a 1 year budget 
difference of before and after DMM introduction of approximately $4,035,796. Our 
study estimated that prior to DMM introduction the per-member-per month (PMPM) 
for AD prescription medications was $0.032, and increased by $0.129 after the 
introduction of DMM for our health plan eligible population of 2.6 million patients. 
For we are expecting these new DMM drugs to be priced at a premium, and despite 
using a conservative estimate of the cost of DMM therapy the model’s sensitivity 
analyses identified cost of DMM as the most influential parameter in the model. With 
the introduction of DMM the total cost ranged from $2,919,148 to $7,162,348 when 
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priced at $1,000 and $3,000 per prescription, respectively and a PMPM from $0.0936 
to $0.2296. Considering that based on the various health plans and the amount 
allocated in terms of PMPM for prescription medications, these PMPM values might 
have an increased, decreased, or no effect on budgets once DMM is introduced.20-22 
Most health plans medication benefits range between $25 to $35 PMPM.20 But, an 
acceptable increase in PMPM for the implementation of a new therapy or drug to be 
considered affordable for health plans is between 0.5%-1%, per the Institute for 
Clinical and Economic Review (ICER) framework. In our study the increase in overall 
cost was significant but when considering the PMPM impact on medication benefits, 
will be within the acceptable 0.5%-1% range when using a $35 PMPM bench mark. In 
terms of the substantial increase in overall cost, given the disease-modifying and 
slowing down of disease progression properties associated with these new medications 
can lead us to assume or expect; that an increase in the drug expenditure associated 
with a DMM therapy may be offset by some of the savings resulting from effect of 
drug in delaying institutionalized high costs. i.e. nursing homes. 
 In determining our model we decided to focus on AD prescription medication 
cost and assumptions on the switching, and adding of DMM to future AD population. 
The study’s focus was not to determine or estimate any off-setting costs or measure 
the impact of other cost sources such as physician visits, hospital visits, or long-term 
facility care. DMM therapy is expected to improve patients’ cognition, function, and 
behavior but as to the implications that might have on utilization cost of other medical 
services remains to be determined once the new therapy reaches the market.4,5,19,23,24 
 Budget impact models are essential methods used by health plans, and 
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hospitals in determining effect and affordability of implementing a new therapy, 
allowing decision- makers to evaluate both the clinical and economic implications on 
medical and pharmacy budgets.13,20-23 
2.6 Limitations 
 Potential limitation of the study was the percentage of patients switching from 
current therapy or adding to their current therapy the new DMM medication. The 
assumptions concerning the new treatment mix may or may not be representative of 
what we might see in terms of utilization of a new DMM therapy. The model 
assumptions concerning that there will be patients switching or adding or first time 
users of DMM was reasonable, and that hospitals or other payers perform using 
similar method when conducting their own budget impacts. Another potential 
limitation was not including any costs other than medication cost, and not showing 
any offsetting costs to other medical services, or side effect costs that introduction of 
DMM might result in, but those would have been difficult to make educated 
assumptions on and would have more reliable data once medication is on the market. 
Further, we know that DMM specifically target patients in the early less severe stages 
of AD and an assessment of disease severity could not be obtained from this database. 
This might be essential in determining a more accurate representation on who would 
be more eligible to use the new therapy. Being a commercial based health care plan 
our results might not be generalized to government or other non-private health care 
plans. 
2.7 Conclusion 
 This study, to the best of our knowledge, is first to predict and quantify a 
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budget impact for a proposed disease-modifying medication for the treatment of 
Alzheimer’s disease. Our model demonstrated a substantial increase in the overall 
total cost after the introduction of the new therapy. The study highlighted that the cost 
of the new therapy will be the main cost factor to the impact seen in budget analyses 
conducted in other health plans, and hospitals. 
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Figure 1. Budget Impact Flowchart 
 
CURRENT TREATMENT                            NEW TREATMENT
                                                                                    
                   
                            Difference=Budget Impact
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filled during 2012
Costs: AD specific 
prescriptions filled in 
2012. AChEIs and 
NMDAs e.g. Donepezil 
and/or Namenda
Cost of Current 
Treatment Mix          
Total Population at Risk 
Alzheimer's Disease (AD) 
(>=55 years old) 
Optum Database (2010-2012)
Target Population:
Continous enrollment 
(2010-2012) with AD 
specific medications 
filled during 2012
Costs: AD specific prescriptions 
filled in 2012. AChEIs and 
NMDAs e.g. Donepezil and/or 
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Table 1. Unit Costs Applied to Base-Case Analysis and Prescription Utilizations 
Among the Drug Classes Before and After Introduction of Disease-Modifying 
Medication (DMM) 
 
BEFOR DMM¹ 
      
       
Resource 
 
Rx² Patients 
Cost ($) / 
Rx 
Rx / 
Patient Reference 
       Alzheimer's 
Medications 
      
       
AChEIs³ 
 
1526 144 147 10.6 
Optum Datamart™ 
(2014 $) 
       
NMDA⁴ 
 
585 44 271 13.3 
Optum Datamart™ 
(2014 $) 
       
AChEI+NMDA 
 
2976 248 209 12 
Optum Datamart™ 
(2014 $) 
       Total 
 
5088 436 
   
       AFTER DMM 
      
       
Resource 
 
Rx Patients 
Cost ($) / 
Rx 
Rx / 
Patient Reference 
       Alzheimer's 
Medications 
      
       DMM 
 
2122 177 2,000 12 Author* 
       
AChEIs 
 
1208 117 147 10.6 
Optum Datamart™ 
(2014 $) 
       
NMDA 
 
461 35 271 13.3 
Optum Datamart™ 
(2014 $) 
       
AChEI+NMDA 
 
2368 202 209 12 
Optum Datamart™ 
(2014 $) 
       Total 
 
6159 530 
   
       1- Disease-Modifying 
Medication  
     2- Prescriptions 
(Rx) 
      3- Acetylcholinesterase Inhibitors e.g. 
Donepezil 
    4- N-Methyl-D-Aspartate e.g. 
Namenda 
     * Calculation using assumptions of expected cost 
and utilization of new drug 
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Table 2. Total Budget Impact: Health Plan of 2.6 Million Members Before and 
After Introduction of Disease-Modifying Medication (DMM) 
 
    Before DMM 
Total ($) [PMPM] 
After DMM Total 
($) [PMPM] 
Incremental Cost ($) Total 
(% Change) [PMPM] 
          
Alzheimer's 
Medications 
        
          
DMM¹   $0  $4,243,200  $4,243,200  
          
AChEI²   $224,380  $177,534  $-46,846 (-20.8)  
          
NMDA³   $158,589  $125,052  $-33,537 (-21.1) 
          
AChEI+NMDA   $621,984  $494,961  $-127,023 (-20.4) 
          
Total Costs   $1,004,954 
[$0.0322] 
$5,040,748 
[$0.1616] 
$4,035,794 (400)  
[$0.1294] 
          
PMPM=per member per month [(Total Cost /# of members 
in health plan) / 12 months] 
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Table 3. Sensitivity Analyses: Total Costs and Per-Member-Per-Month (PMPM) 
Costs After Introduction of Disease-Modifying Medication (DMM) 
 
Total Cost     
Base Case $5,040,748.69   
      
  LOW HIGH 
Percentage Adding to DMM ±50% $4,510,348.69  $5,571,148.69  
Percentage Switching to DMM ±50% $4,090,401.66  $5,991,095.72  
New Cases for DMM Utilization 
±50% $4,483,828.69  $6,101,548.69  
AD Medications Utilization ±50% $3,050,774.34  $7,030,723.03  
Cost of DMM ±50% $2,919,148.69  $7,162,348.69  
      
Total PMPM     
Base Case $0.1616   
      
  LOW HIGH 
Percentage Adding to DMM ±50% $0.1446  $0.1786  
Percentage Switching to DMM ±50% $0.1311  $0.1920  
New Cases for DMM Utilization 
±50% $0.1437  $0.1956  
AD Medications Utilization ±50% $0.0978  $0.2253  
Cost of DMM ±50% $0.0936  $0.2296  
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Figure 2. Tornado Diagram: Sensitivity Analyses Per-Member-Per-Month 
(PMPM) Cost For Model Parameters After Introduction of Disease-Modifying 
Medication (DMM) 
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3.1 Abstract  
 Our purpose was to estimate direct cost of care for patients newly diagnosed 
with Early-Onset Dementia (EOD), age 21-64 years old, and evaluating predictors on 
total cost using a Generalized Linear Model (GLM). The sample was drawn from 
Optum Clinformatics™ Data Mart, a large national insurer database with 
administrative health claims information collected for up to 3 years from a private 
health plan. Direct cost included cost for dementia-related services associated with 
settings in: outpatient, inpatient, and long-term care, as well as prescription 
medications for dementia. Patient characteristics, considered and analyzed by the 
model, included age, gender, EOD subtypes, geography, and comorbidities. Total 
direct cost per patient was $10,932 (SD $27,612) with a 66.7% increase in total cost 
seen among patients in the Midwest, a 43.9% and 38.7% increase in patients age 32-42 
years old and 43-53 years old, respectively. Total direct cost of EOD patients increased 
considerably in various clinical and demographic variables. Age; 32-42 years-old, 43-
53 years old, Geography; Midwest region, Comorbidity; hypertension, depression, and 
rheumatoid arthritis, were all associated with the highest direct cost..  
3.2 Introduction  
 Dementia has become a public health concern given the U.S. aging population, 
and although often associated with old age few studies estimate 220,000 to 640,000 of 
Americans suffer from Early-Onset Dementia (EOD)1-3 comprising 1-5% of all 
dementia cases. EOD is defined, arbitrarily, as individuals suffering from dementia 
symptoms under the age of 65, while still having the same symptoms and subtypes as 
seen in the older population in that Alzheimer’s Disease, Vascular Dementia, Lewy 
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Body Dementia, and Frontotemporal Dementia are all identified in EOD.1-3 EOD has 
an impact affecting people in their productive years of life holding both professional 
and personal responsibilities when the disease strikes them.3-5 The burden of disease is 
both personal and economic, impacting the patients, their families, communities, and 
the health care system. The literature is scarce regarding the prevalence and incidence 
of EOD, and despite the high financial implication of dementia most of the analysis of 
cost burden have paid little attention to EOD compared to dementia with age of onset 
65 or older.3-6 This study aimed to provide information describing the direct cost of 
care associated with EOD and how patient clinical and demographic characteristics 
impact that total cost. 
3.3 Methods  
 The primary data source was the Optum Clinformatics™ Data Mart, a large 
national insurer database with administrative health claims information for 
approximately 19 million patients, collected from January 2010 to December 2012. 
Available information about these patients with private insurance included: member 
demographics, medical claims, pharmacy claims, lab results, and inpatient claims. 
 The study population was comprised of patients with only a single subtype 
EOD categorized by following etiologies: Mild Cognitive Impairment (MCI), 
Alzheimer’s Disease (AD), Vascular Dementia (VD), Frontotemporal Lobar Dementia 
(FTD), Lewy Body Dementia (LBD), and Dementia Non-Specific (DNOS) that does 
not fit in the previous mentioned diagnoses.1,2 Age, gender, dementia subtypes, 
geographic locations by states, and comorbidities were the patient characteristics 
considered and analyzed.  
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 Population selection was as follows: diagnosis associated with EOD etiologies 
in accordance with the International Classification of Disease 9th Edition Clinical 
Modification [ICD-9-CM] medical codes. Relevant codes were reviewed and selected 
from the Agency for Healthcare Research and Quality (AHRQ), using the Clinical 
Classification Software (CCS) from the Healthcare Cost and Utilization Project 
(HCUP). The Clinical Classification Software (CCS) for ICD-9-CM is a tool 
developed for HCUP sponsored by AHRQ, which provides over 14,000 diagnosis 
codes and 3,900 procedure codes. Continuous enrollment was required for a minimum 
of 18 months to allow for a look back of 365 days to capture the newly diagnosed 
cases, and then only consider the new cases that had a minimum of 12 month follow 
up to estimate cost of care. Early-Onset newly diagnosed dementia patient ages’ 21 to 
64 years old inclusive, and excluding any patients with a cancer diagnosis. Cancer 
diagnosis is associated with high cost of care and would introduce bias in our cost 
estimates for newly diagnosed EOD patients. To meet the newly diagnosed criteria we 
concentrated on incident cases or first time diagnosis, which was determined by our 
365 days look back period among patients with 18 months continuous enrollment. 
Patients that recorded a diagnosis of dementia that was less than 365 days were 
captured. This helped us make the assumption that the patients did not come into the 
cohort with the diagnosis previously. 
 Two analytic samples were created comprising patients with EOD as primary, 
secondary or any other diagnosis, and patients having EOD as their primary diagnosis 
only. EOD as primary diagnosis only was used for cost analysis (i.e. expenses for 
services associated with EOD care) and descriptive characteristics, while the group 
 61 
 
identified with EOD codes as primary or non-primary diagnoses was also analyzed to 
describe characteristics of the overall EOD population. (Figure 1). Study outcome 
(dependent variable) was total annual per-patient cost for all health care service use 
associated with care for EOD, with independent variables represented by: age, gender, 
EOD subtypes, geography, and comorbidities.  
 Age was grouped into separate categories: 21-31 years old (Category1), 32-42 
(Category2), 43-53 (Category3), and 54-64 (Category4). Gender separated into male 
and female. EOD subtypes were represented by: MCI, AD, LBD, VD, FTD, and 
DNOS. Geography was categorized as U.S. regions: Northeast, South, Midwest, and 
West. Comorbidities were defined and searched using the Elixhauser Comorbidities 
Index having the following comorbidity items included:7 congestive heart failure, 
cardiac arrhythmias, valvular disease, pulmonary circulation disorders, peripheral 
vascular disorders, hypertension, paralysis, chronic pulmonary disease, diabetes, 
hypothyroidism, renal failure, liver disease, peptic ulcer disease, AIDS/HIV, 
rheumatoid arthritis, coagulopathy, obesity, weight loss, fluids and electrolyte 
disorders, blood loss anemia, deficiency anemia, alcohol abuse, drug abuse, 
psychoses, depression, other mental disorders. Patients were categorized as: no 
comorbidity or any comorbidity, with any comorbidity representing patients with 0,1, 
2 or more of the above searched comorbidities.  
 Total annual per-patient cost, as the dependent variable, included Outpatient 
care, Inpatient stay, Long-Term Facility stay, and Prescription drugs were dementia 
specific medications: Anticholinesterase Inhibitors (AChEIs) e.g. Donepezil, and 
NMDAs e.g. Memantine, . Outpatient care included: office visits, home care, urgent 
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care facility, outpatient hospital, and ambulatory surgical center. Inpatient stays 
included sites: inpatient hospital, emergency room visits, inpatient psychiatric facility, 
and partial hospitalization-psychiatric facility. Long-Term Facilities included: skilled 
nursing home facility, nursing facility, custodial care facility. Outpatient, inpatient, and 
long-term facilities were defined using the American Medical Association (AMA) 
Current Procedural Terminology (CPT) Manual. Costs represented amount charged to 
the insurer, minus patient coinsurance, copay or patient out of pocket payments 
towards their deductible. 
 Differences in mean total costs between the variable categories were assessed 
using an ANOVA test. While evaluating the relationship between total cost and 
covariates of interest, and because of the skewed nature of cost, we utilized a 
Generalized Linear Model (GLM).8-10 Predictors of cost were determined using the 
GLM using a forward predictive approach, and implementing Modified Park test to 
determine dependent variable distribution.8-10 GLM was best method for the model 
using a “link” and “family” function due to skewed nature of the cost variable, and 
since log transformation could not achieve normality using Ordinary Least-Squares 
(OLS).8-11 We used the link function to specify the relationship between the mean of 
our outcome variable, total cost, and predictors.8-11 While family function which 
corresponds to the distribution of data which in this case was a Gamma distribution 
informed by the Modified Park Test.8-11 
 For all analyses, statistical significance was considered a 2-sided P-value 
<0.05. All statistical analyses were performed using SAS version 9.4 (SAS Institute, 
Cary, NC). This study was reviewed and approved as exempt by the University of 
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Rhode Island’s Institutional Review Board.  
3.4 Results  
 The cohort sample was created after applying inclusion and exclusion criteria 
(Figure 1): patients with primary diagnosis of any subtype of dementia (n=2,150) were 
used for the descriptive statistics presented in Tables 1 and 2, health service utilization 
(Table 3), and used for the  development of the GLM used for our cost analysis.  
 We initially identified 42,226 patients, from total number of 19 million patients 
with approximately 2 in 1,000 prevalence, having at least one primary or non-primary 
diagnosis for dementia (Figure 1); from which 13,185 patients were excluded for not 
being continuously enrolled for a minimum of 18 months. A further 21,120 patients 
were excluded for being older than 64 years of age or younger than 21 years of age. 
An additional 96 patients were excluded for having a cancer diagnosis. 
 In the sample frequency demographic (n=2150) of newly diagnosed EOD 
patients in our Table 1, females comprised 1183 (55.03%) of the population while 
males account for 967 (44.97%). The age variable was divided into four categories 
with patients aged 54-64 years old comprising 1198 (55.7%) of the population 
followed by those age 43-53 years old accounting for 516 (24%); while those age 32-
42 years old were 250 (11.62%), and accounting for the remaining cases were the 21-
31 years old with 186 (8.65%). As for the various dementia subtypes the frequencies 
were as follows: MCI 1001 (46.55%), Dementia-NOS 762 (33.4%), AD 243 (11.3), 
VD 101 (4.69%), FTD 30 (1.39%), and LBD 13 (0.61%). Dementia Non-Specific 
(NOS) represents dementia that had a diagnosis code of dementia that did not fit any 
of the other more specific subtypes. The majority of our population was found in the 
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South 994 (46.23%), followed by the Midwest 444 (20.65%), and with the West and 
Northeast at similar frequencies of 358 (16.65%) and 354 (16.64%), respectively. 
Final variable of interest was comorbidity and whether patients had any of the 
Elixhauser comorbidities, patients were divided into having; 0, 1, 2 or more 
comorbidity. Patients with only 1 comorbidity accounted for 956 (44.4%), while 
patients with 2 or more comorbidity recorded 661 (30.9%). The remaining group of 
533 (24.7%) recorded no or 0 comorbidity. In our Table 2 (n=2,150) we provide 
descriptive statistics of sample frequencies in patients categorized by dementia 
subtypes.  
 Among patients with EOD documented as Mild Cognitive Impairment  
(MCI, n=1001) we found a statistically significant difference by Geographical regions 
(P-value<0.0001) with majority of our cohort residing in the South (n=467; 46.65%). 
Most patients with MCI recorded at least 1 or more diagnosis for a relevant diagnosis, 
showing statistically significant difference in Comorbidity variable (P-value=0.017). 
MCI patients 240 (23.98%) documented no comorbidity, 477 (47.65%) accounted for 
having 1 comorbidity only, and remaining 284 (23.67%) MCI patients recorded 2 or 
more comorbidity. Differences in MCI prevalence by age or gender were not 
statistically significant. (P-values=0.073 and 0.58, respectively).   
 Among patients having an EOD documented as Alzheimer’s Disease (AD, 
n=243), there was no statistically significant difference in frequencies among the 
various Age Categories (P-value=0.22), no difference in gender (P-value=0.05), no 
difference among Geographical regions (P-value=0.58), and no statistically significant 
difference between the Comorbidity Categories (P-value=0.27). 
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 Among patients with a diagnosis of Lewy Body Dementia (LBD, n=19), 
Frontotemporal Dementia (FTD, n=49), and Vascular Dementia (VD, n=212) no 
statistically significant difference (P-values >0.05) was found in the relationship of 
having a diagnosis of one of those subtypes and in any of our variable of interests of; 
Age, Gender, Geography, or Comorbidity.  
 Finally, among patients with Dementia-NOS (n=762) statistically significant 
differences was found in Age, Geography, and Comorbidity. Age 54-64 years old was 
the majority of Dementia-NOS patients at 405 (53.15%) and the least cases at 71 
(9.32%) in the 21-31 years old category (P-value=0.04). Most of the Dementia-NOS 
patients were located in the South 329 (43.18%) followed by the Midwest 189 
(24.8%), the remaining split between Northeast 136 (17.85%) and West 108 (14.17%) 
(P-value=0.0004). Dementia-NOS patients with 0 or no comorbidity were 184 
(24.15%) followed by 312 (40.94%) with 1 comorbidity, and remaining 266 (16.79%) 
with 2 or more comorbidity (P-value=0.013). Gender showed no statistically 
significant difference in Dementia-NOS patients (P-value=0.16). 
 In Table 3 we present the frequency and percentage of patients utilizing 
outpatient and inpatient services, long-term care and prescription medication for 
dementia, for events associated with a primary diagnosis of dementia (n=2,150 
patients). All patients had at least 1 outpatient visit for dementia, as this was a study 
inclusion criterion, and thus we did not apply a test for statistical significance. Among 
these 2,150 patients, 205 (9.5%) had at least 1 inpatient stay. A majority of these 
patients (n=1001, 46.5%) were diagnosed with MCI, 30.7% had a diagnosis of 
Dementia-NOS, while 11.3% had a diagnosis of AD. Statistically significant 
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differences were observed among the frequency of inpatient stays by Geography (P-
value=0.0008) with largest inpatient stays occurring in the South (n=94, 45.5%) 
followed by the Midwest (n=61, 29.7%). Inpatient stay statistically significant 
difference was seen in comorbidity categories (P-value <0.0001) with patients (n=105, 
51.22%) having 2 or more comorbidity had an inpatient stay compared to patients 
(n=89, 43.41%) with 1 comorbidity, and patients (n=11, 5.37%) having no or 0 
comorbidity having an inpatient stay.  
 For Long-Term Facility (LTC) stay we have patients (n=43, 2%) that entered 
LTC. Statistically significant differences, for LTC stay, in frequencies among the 
variables was found in the Geography variable (P-value <0.0001) and Comorbidity 
variable (P-value=0.0003). Patients (n=19, 44.1%) with LTC stay were found mostly 
in the Midwest. Patients (n=23, 53.49%) with 2 or more comorbidity had LTC stay 
compared to patients (n=19, 44.19%) that had 1 comorbidity having LTC stay. 
 Finally, patients (n=79, 3.6%) recorded prescription dementia drugs being 
filled.   Statistically significant differences in frequencies among the variables was 
found in the Comorbidity categories (P-value=0.005). Patients (n=43, 54.43%) with 1 
comorbidity recorded filling prescriptions for dementia medications compared to 
patients (n=27, 34.18%) with no or 0 comorbidity, and patients (n=9, 11.39%) with 2 
or more comorbidity when filling prescriptions for dementia medications. Some 
notable counts captured showed that of the 79 prescriptions filled; 20 MCI patients, 25 
AD patients, and 30 Dementia-NOS patients had dementia specific drugs filled. 
 Following the care setting frequencies we estimated the mean and total cost, in 
dollars, of each care setting during a 12-month time frame for our new cases of 
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primary EOD diagnosis (n=2,150),  as presented in Table 4.  
 Total cost for each setting was as follows: outpatient (n=2,150, 100%) was 
approximately $16.1million, inpatient (n=205, 9.5%) was approximately $6.6million, 
LTC (n=43, 2%) was $560,755 and Rx (n=79, 3.6%)) was $ 146,597 yielding a total 
cost of care at approximately $23.5million for these 2,150 newly diagnosed patients 
with primary EOD diagnosis. Mean cost per care setting when utilized by this cohort 
(n=2,150) results in: outpatient cost approximately $7,524 (SD=$19,123), inpatient 
cost approximately $3,079 (SD=$16,275), LTC cost approximately $260 
(SD=$2,441), and total mean cost of all services approximately $10,932 
(SD=$27,612). 
 These costs differ from the mean cost per patient in each care setting utilized, 
yielding the following results: outpatient (n=2,150, 100%) cost approximately $7,524 
(SD=$19,123), inpatient (n=205, 9.5%) cost approximately $32,300 (SD=$42,918),  
LTC (n=43, 2%) cost approximately $13,040 (SD=$11,587), and Rx (n=79, 3.6%) cost 
approximately $1,855 (SD=$2,427).  
 In Table 5 we provide descriptive statistics of the total cost given the specific 
care settings in each of our variables, and determining statistical significance among 
the variable categories’ cost using an ANOVA test.  
 Outpatient visits showing statistically significant differences were found in 
patients with comorbidities (P-value <0.0001), where patients with no or 0 
comorbidity averaged a direct cost of $2,469 (SD=$3,652) compared to patients with 1 
comorbidity $8,819 (SD=$24,938), and $9,726 (SD=$20,327) in patients with 2 or 
more comorbidity. No statistically significant difference was shown in outpatient visit 
 68 
 
cost among the various Age categories (P-value=0.11), or in Gender (P-value=0.96), 
or among the various dementia Subtypes (P-value=0.82), or Geographical regions (P-
value=0.18).   
 Inpatient stay showing statistically significant differences were found among 
the Age categories (P-Value=0.008) with 21-31 years old having a mean cost of 
$66,159 (SD=$95,155), followed 54-64 years old with $31,614 (SD=$37,008), 43-53 
years old at $28,685 (SD=$33,217), and the lowest mean cost of $17,892 
(SD=$20,417) among32-42 years old. Statistically significant differences were shown 
in Geographical regions (P-value=0.01) with the West averaging $48,335 
(SD=$74,695), followed by the Northeast at $39,293 (SD=$49,094), the Midwest at 
$38,811 (SD=$44,959), and the South at $22,526 (SD=$26,526). In addition, 
statistically significant difference was shown in Comorbidity categories with $17,426 
(SD=$2,791) in patients with 0 comorbidity compared to $24,803 (SD=$26,449) in 
patients with 1 comorbidity, and $42,982 (SD=$56,427) in 2 or more comorbidity. 
Gender (P-value=0.72), and dementia Subtype (P-value=0.06) all showed no 
statistically significant differences in mean cost in each of the specific variable 
categories for inpatient stay.  
  Long-Term Facility (LTC) stay, showed no statistically significant differences 
in mean cost LTC stay among our variables of interest: Age (P-value=0.85), Gender 
(P-value=0.94), dementia Subtypes (P-value=0.91), Geography (P-value=0.51), and 
Comorbidity (P-value=0.43).  
 Prescription drugs (Rx), dementia specific medications, mean cost showed no 
statistically significant differences among the variables of interest: Age (P-
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value=0.49), Gender (P-value=0.55), dementia Subtypes (P-value=0.94), and 
Geography (P-value=0.68). Comorbidity (P-Value=0.01) showed statistically 
significant differences in the mean cost, with $1,371 (SD=1,995) in patients with 0 
comorbidity compared to $1,942 (SD=2,154) in patients with 1 comorbidity, and 
$2,893 (SD=$4,254) with 2 or more comorbidity. All 79 patients with dementia 
prescription drugs filled recorded No comorbidity.  
 Using GLM we identified several statistically significant (P-values <0.05) 
predictors of cost as seen in Table 6: Age 43-53 years old, Midwest region, and 
Comorbidity. Comorbidities with most impact included: Chronic Heart Failure (CHF), 
Hypertension (HTN), Cardiac Arrhythmias (CARDARR), Psychoses (PSYCH), 
Chronic Pulmonary Disease (CHRLUNG), Rheumatoid Arthritis (ARTH), Deficiency 
Anemia (ANEMDEFF), Coagulopathy (COAG), Pulmonary Circulations 
(PULMICRC), Peripheral Vascular Disorders (PERIVASC), Valvular Disease 
(VALVE), Fluid and Electrolyte (LYTES). 
 The model developed estimated that mean direct total cost of care in newly 
diagnosed patients with Early-Onset Dementia (EOD) was $10,932 (SD=$27,612); an 
increase of  up to 66.7% in patients living in the Midwest compared to the South as the  
reference, increase of 38.7%  in 43-53 years old when compared to the reference 21-
31 years old. Increases in mean total cost of care having specific comorbidities, when 
compared to the absence of the comorbidity, were as follows: 664.1% (or 6.6 times) in 
patients diagnosed with CHF as a comorbidity, 62.4 % (or 1.6 times) with HTN, 
263.5% (or 2.63 times) with CARDARR, 62.2% (or 1.6 times) with PSYCH, 82.2% 
(or 1.8 times) with CHRNLUNG, 87.8 % (or 1.8 times) with ARTH, 101.4% (or 2 
 70 
 
times) with ANEMDEFF, 148.5% (or 2.5 times) with COAG, 318% (or 3.1 times) with 
PULMCIRC, 125.6% (or 2.2 times) with PERIVASC, 155.7 % (or 2.5 times) with 
VALVE, and 324.1% (or 3.2 times) with LYTES.  
Our Table 7 compares the mean cost of all the significant predictors, from our GLM, 
versus the mean cost of the reference compared with. In Age category (reference 21-
31 years old vs predictor 43-53 years old); $10,474 (SD=$37,106) vs $12,078 
(SD=$27,448), Region Category (reference South vs predictor Midwest); $9,812 
(SD=$20,771) vs $15,081 (SD=$40,509), CHF comorbidity (reference CHF absent vs 
CHF present); $10,061 (SD=$25,730) vs $53,609 (SD=$62,528), HTN; $10,062 
(SD=$28,724) vs $13,154 (SD=$24,426), CARDARR; $9,410 (SD=$25,927) vs 
$24,284 (SD=$36,891), PSYCH; $10,823 (SD=$27,514) vs $17,929 (SD=$33,012), 
CHRNLUNG; $10,788 (SD=28,177) vs $13,177 (SD=17,309), ARTH; $10,924 
(SD=$27,754) vs $11,570 (SD=$13,418), ANEMDEFF; $10,710 (SD=$27,079) vs 
$16,620 (SD=$38,622), COAG; $10,894 (SD=$27,624) vs $16,429 (SD=$26,042), 
PULMCIRC; $10,646 (SD=$27,112) vs $31,146 (SD=$39,171), PERIVASC; 
$10,771.39 (SD=$27,440) vs $25,238 (SD=38,117), VALVE; $10,596 (SD=$27,546) 
vs $21,078 (SD=$28,749), LYTES; $10,523 (SD=$26,204) vs $32,511 (SD=$66,268). 
Dementia patients with 1 or more comorbidities can expect an increased overall cost 
of care, with cardiac comorbidities being the greatest contributors to cost. 
3.5 Discussion  
 In this study, we estimated the total direct mean cost for disease specific 
patients with Early-Onset Dementia (EOD), and determined patients’ clinical and 
demographic predictors of the overall care cost. The purpose of our study was to 
 71 
 
provide a source of cost information for an underrepresented population in studies 
conducted in both cost, and epidemiology fields.1,3,12,13 We estimated an annual per-
patient direct cost for medical care among newly diagnosed cases of EOD of $10,932 
(SD=$27,612). In addition we have the cost breakdown for each of the medical care 
settings, providing context and cost information to guide allocation of resources when 
planning healthcare services for patients with EOD. With cost analyses for Early-
Onset Dementia difficult to find we relied on cost information studies for Dementia 
and Alzheimer’s in Late-Onset (>65years) patients to compare with our findings. 
Given that there currently no treatment is available for dementia the type of care 
setting and services for both Early-Onset and Late-Onset are expected to be 
similar.13,14 Zhu et al., in a 2006 Alzheimer’s study consisting of a cohort across 3 US 
medical facilities found a total direct mean cost per-patient equal to $12,587 
(SD=$20,849) over a 4 year period. This study categorized care settings as: outpatient 
treatment, hospitalization, and medications with no Long-term Facility cost 
recorded.15,16 In a 2011 systemic literature review study, by Mauskopf and Mucha, on 
direct and indirect medical and non-medical cost across the different level of severity 
in Alzheimer’s disease; found that the mean direct cost in mild Alzheimer’s in 19 
studies from 1993-2009 ranged approximately between $4,000 to as high as $19,000 
per patient. Most of the studies collected by Mauskopf categorized the direct cost 
under outpatient, inpatient, medications and with a few including cost of Long-Term 
Facility care.17 Murman et al. 2007 in evaluating the direct cost of care in degenerative 
dementia patients found an approximate mean of $17,000. In the Murman study 
Nursing Home care costs were included in addition to the outpatient, inpatient, and 
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medication costs.18,19  
 Our study focused on the total cost increases of the medical care settings that 
occurred in patients with specific clinical and demographic characteristics. In this 12 
month period higher costs were associated with ages 43-53 years old, the Midwest 
region, and specific comorbidities. Dementia subtype patients were diagnosed with 
were not a predictor of cost, and neither was gender. 
 The majority, approximately 75%, of new cases with EOD as a primary 
diagnosis in our patient population, were diagnosed as either Mild Cognitive 
Impairment (MCI) or DNOS and 10% having an Alzheimer’s disease (AD) diagnosis.  
In this study the variable of Gender showed no statistically significant difference in 
terms of frequency of medical care setting utilization or their cost, or in frequencies 
among the various dementia subtypes except in AD were more females (60%) than 
males (40%) where diagnosed (P-value=0.05).  
 In this study we showed a direct relationship between increased cost of care in 
EOD patients per number comorbidities. We included each of the captured 
comorbidities into our model to estimate the ones associated with higher costs. Results 
showed that:  
congestive heart failure (CHF), hypertension (HTN), Cardiac Arrhythmias 
(CARDARR), Psychoses (PSYCH), Chronic Pulmonary Disease (CHRLUNG), 
Rheumatoid Arthritis (ARTH), Deficiency Anemia (ANEMDEFF), Coagulopathy 
(COAG), Pulmonary Circulations (PULMCIRC), Peripheral Vascular Disorders 
(PERIVASC), Valvular Disease (VALVE), and Fluid and Electrolyte Disorders 
(LYTES) were associated with increased cost of care. In Figure 2 all the predictor 
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costs were plotted against our total mean cost $10,932 (SD=$27,612), and having 
Congestive Heart Failure (CHF), Cardiac Arrhythmias (CARDARR), and three other 
comorbidities as the predictors showing statistically significant difference from our 
total mean cost $10,932 (SD=$27,612). Patients with cardiac comorbidities can expect 
an increased utilization of care settings and producing the higher costs. 
 We found cost differences across Geographical regions, attributed to 
differences seen in terms of care setting utilizations and cost among dementia patients 
across the US.20-23 Patients in the Midwest showed the highest cost when compared to 
the other three regions of the country. These variations in cost across regions may be 
due to regional pricing differences, availability of services, socioeconomic differences, 
ethnic and racial differences which would need further examination16,20-23.  
 We found the most frequent EOD was either MCI or DNOS, but with none of 
the types being a predictor of cost in our overall model. Expectations was that AD 
would account for majority of the diagnosis given that the few estimations found in 
the literature show that AD would account for about 30% of all EOD.3,5,6,23 In addition 
most of the cost analyses done specifically target dementia and AD in ages 65 and 
older making it difficult to have comparable values in EOD patients, and relying on 
the assumption and the expectation that costs seen in EOD, and specifically AD, 
mirror what is produced in the older patient groups.  
3.6 Limitations  
 There are several limitations in our study. The database did not provide 
information on race, education level, income or marital status, and these factors may 
have been associated with cost differences. The cost information collected was total 
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direct cost for dementia care, and not incremental costs associated with development 
of the disease. In order to produce the incremental cost we would have to develop a 
non-EOD patient group with similar characteristics of those of our EOD to show the 
increasing or decreasing cost between developing EOD and not having EOD. 
However, this was not the main concern of the study as we were trying to provide a 
descriptive informative review on direct costs associated with services for EOD and its 
subtypes. Being a commercial based health care plan our results might not be 
generalized to government or other non-private health care plans. 
3.7 Conclusion  
 Results of our study provided needed information for the direct cost in Early-
Onset Dementia patients. The study highlighted the significant variation of cost 
estimates for the different care settings of interest, and producing a total mean direct 
cost of care $10,932 (SD=$27,612) per patient. The study in addition provided an 
understanding of predictors associated with higher cost in the Early-Onset Dementia 
population; where patients with specific comorbidities were associated with increased 
cost, patients 43-53 years old recorded higher mean cost, and patients living in the 
Midwest region of the U.S. seen with higher costs. In providing these type of cost-of-
illness studies decision makers are more informed as to the implications, and 
distribution of these direct cost on the Early-Onset Dementia population. 
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Figure 1. Population Flowchart 
 
OPTUM DATA (2010-2012)
All Dementia events having a single
1° or 2° or 3° or 4° or 5° diagnosis of
any of the Dementia Subtypes:
Alzheimer's Disease, Lewy Body Disease,
Frontotemporal Dementia, Vascular Dementia
and Dementia Non-Specified
(N=42,226)
Continous Enrollment for a minimum of 18 months NO Exclusion:
(N=29,041) (N=13,185)
Age 21 to 64 years old, inclusive NO Exclusion:
(N=7,921) (N=21,120)
Patients with no Cancer Diagnosis NO Exclusion:
(N=7,825) Patients with Cancer Diagnosis
(N=96)
Patients with diagnosis first date < 365 days
and has follow-up minimum of 12 months NO Exclusion:
(N=4,902) (N=2,923)
Patients with 1° diagnosis 
(N=2,150)
*Cohort used for cost analysis  
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Table 1. Sample Frequency Demographic and Clinical Characteristics of Newly 
Diagnosed Early-Onset Dementia (EOD) patients 
 
Sample Size (N) 2150 
Variables  
Age Category, Yrs, N (%)   
   21-31 186 (8.65%) 
   32-42 250 (11.62%) 
   43-53 516 (24%) 
   54-64 1198 (55.7%) 
Gender, N (%)   
   Female 1183 (55.03%) 
   Male 967 (44.97%) 
Subtypes, N (%)   
   MCI¹ 1001 (46.55%) 
   AD² 243 (11.3%) 
   LBD³ 13 (0.61%) 
   FTD⁴ 30 (1.39%) 
   VD⁵ 101 (4.69%) 
   Dementia NOS⁶ 762 (35.44%) 
Geography, N (%)   
   Northeast 354 (16.46%) 
   South 994 (46.23%) 
   Midwest 444 (20.65%) 
   West 358 (16.65%) 
Comorbidity, N (%)   
   No Comorbidity 533 (24.7%) 
   1  956 (44.4%) 
   2 or more⁷ 661 (30.9%) 
1 - Mild Cognitive Impairment   
2 - Alzheimer's Disease   
3 - Lewy Body Disease   
4 - Frontotemporal Dementia   
5 - Vascular Dementia   
 6 - Dementia Non-Specific characteristic under senile or 
pre-senile dementia 
  
 7- Had at least 2 and up to 4 comorbidities   
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Table 2. Descriptive Statistics of Sample Frequency Demographic and Clinical 
Characteristics in Newly Diagnosed Patients with specific Early-Onset Dementia 
Subtypes 
 
 MCI AD LBD FTD VD Dementia 
NOS 
Sample Size 
(N=2150) 
1001(46.55%) 243 (11.3%) 13 (0.61%) 30 (1.39%) 101 (4.69%) 762 (33.4%) 
Variables       
       
Age Category, 
Yrs, N (%) 
            
   21-31 86 (8.59%) 22 (9.05%) < 5** < 5 < 5 71 (9.32%) 
   32-42 105 (10.49%) 24 (9.88%) < 5 < 5 12 (11.88%) 107 
(14.04%) 
   43-53 264 (26.37%) 48 (19.75%) < 5 7 (23.33%) 17 (16.83%) 179 
(23.49%) 
   54-64 546 (54.55%) 149 (61.32%) 11 (84.62%) 19 (63.33%) 68 (67.33%) 405 
(53.15%) 
P-Value 0.073 0.22 Not 
Reported 
0.77 0.05 0.04* 
       
Gender, N (%)             
   Female 557 (55.64%) 148 (60.91%) 4 (30.77%) 14 (46.67%) 56 (55.45%) 404 
(53.02%) 
   Male 444 (44.36%) 95 (39.09%) 9 (69.23%) 16 (53.33%) 45 (44.55%) 358 
(46.98%) 
P-Value 0.58 0.05 0.07 0.35 0.93 0.16 
       
Geography, N (%)             
   Northeast 158 (15.78%) 36 (14.81%) < 5 6 (20%) 18 (17.82%) 136 
(17.85%) 
   South 467 (46.65%) 120 (49.38%) 7 (53.85%) 15 (50%) 56 (55.45%) 329 
(43.18%) 
   Midwest 175 (17.48%) 52 (21.41%) < 5 8 (26.67%) 17 (16.83%) 189 (24.8%) 
   West 201 (20.08%) 35 (14.4%) < 5 1 (3.33%) 10 (9.9%) 108 
(14.17%) 
P-Value <0.0001* 0.58 Not 
Reported 
0.25 0.12 0.0004* 
       
Comorbidity, N 
(%) 
            
   No Comorbidity 240 (23.98%) 73 (30.04%) < 5 10 (33.33%) 22 (21.78%) 184 
(24.15%) 
   1  477 (47.65%) 104 (42.8%) 5 (38.46%) 16 (53.33%) 42 (41.58%) 312 
(40.94%) 
   2 or more 284 (23.67%) 66 (12.76%) < 5 4 (13.34%) 37 (36.64%) 266 
(16.79%) 
 P-value 0.017* 0.27 0.07 0.19 0.11 0.013* 
* p < 0.05 
** < 5 are cells 
that recorded 
under 5 counts 
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Table 3. Descriptive Statistics of Utilization given the specific Care Setting in 
Early-Onset Dementia Patients 
 
 Outpatient¹ Inpatient² Long Term Care³ 
(LTC) 
Prescription Drugs⁴ 
(Rx) 
Sample Size (N=2150) 2150 (100%) 205 (9.53%) 43 (2%) 79 (3.67%) 
Variables     
     
Age Category, Yrs, N (%)         
   21-31 186 (8.65%) 15 (7.31%) < 5** < 5 
   32-42 250 (11.62%) 16 (7.8%) < 5 < 5 
   43-53 516 (24%) 54 (26.34%) 9 (20.93%) < 5 
   54-64 1198 (55.7%) 120 (58.53%) 30 (69.76%) 76 (96.21%) 
P-Value  0.245 0.281 Not reported 
     
Gender, N (%)         
   Female 1183 (55.03%) 107 (52.19%) 19 (44.18%) 41 (51.9%) 
   Male 967 (44.97%) 98 (47.81%) 24 (55.82%) 38 (48.1%) 
P-Value  0.391 0.149 0.569 
     
 Subtypes, N (%)         
   MCI 1001 (46.55%) 63 (30.73%) < 5 20 (25.31%) 
   AD 243 (11.3%) 21 (10.24%) < 5 25 (31.64%) 
   LBD 13 (0.61%) 3 (1.46%) < 5 < 5 
   FTD 30 (1.39%) 3 (1.46%) < 5 < 5 
   VD 101 (4.69%) 17 (8.29%) < 5 < 5 
Dementia NOS 762 (35.44%) 98 (47.8%) 33 (76.74%) 30 (37.97%) 
P-Value  <0.0001* Not reported Not reported 
     
Geography, N (%)         
   Northeast 354 (16.46%) 31 (15.12%) 12 (27.9%) 8 (10.12%) 
   South 994 (46.23%) 94 (45.58%) 10 (23.25%) 37 (46.83%) 
   Midwest 444 (20.65%) 61 (29.75%) 19 (44.18%) 18 (22.78%) 
   West 358 (16.65%) 19 (9.26%) 2 (4.65) 16 (20.25%) 
P-Value  0.0008* <0.0001* 0.419 
     
Comorbidity, N (%)         
   No Comorbidity 533 (24.7%) 11 (5.37%) < 5 27 (34.18%) 
   1  956 (44.4%) 89 (43.41%) 19 (44.19%) 43 (54.43%) 
   2 or more 661 (30.9%) 105 (51.22%) 23 (53.49%) 9 (11.39%) 
P-value  <0.0001* <0.0001* 0.005* 
     
1 - Outpatient includes : Physician Office Visits, Urgent Care Facility, Ambulatory Center, and Outpatient Hospital 
2 - Inpatient includes : Inpatient Hospital, Emergency Room Visits 
3 - Long Term Care includes : Home Care, Skilled Nursing, Nursing facility 
4 - Prescription Drugs : Dementia Specific Medications (AChEIs, and NMDAs)   
* p < 0.05 
** < 5 are cells that 
recorded under 5 counts 
        
 
 
 
 
 
 83 
 
 
 
Table 4. Mean and Total Cost ($) of Care Settings in Early-Onset Dementia 
Patients during a 12-Month Time Period 
 
 Outpatient Inpatient LTC Rx Total 
Sample Size (N=2,150) 2150 205 43 79  
            
Total Cost of service, ($) $16,176,849 $6,621,504 $560,755 $146,597 $23,505,699 
      
Mean Cost per service, $ (SD)  
denominator N=2150 
$7,524.11 
(19,123.13) 
$3,079.77 
(16,275.37) 
$260.8 
(2,441.08) 
$68.18 
(579.56) 
$10,932.88 
(27,612.16) 
      
Mean Cost per patient using the 
service, $ (SD)  
denominator N=patient size 
utilizing service 
$7,524.11 
(19,123.13) 
$32,300.02 
(42,918.16) 
$13,040.82 
(11,587.33) 
$1,855.66 
(2,427.94) 
 
       
Median Cost per patient, $ $3,098.46 $16,878.82 $9,048.66 $1,098.24 $3,378.97 
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Table 5 Descriptive Statistics of Total Mean Cost ($) of Care Settings in 
Demographic and Clinical Characteristics of Early-Onset Dementia Patients, 
during a 12-month Time Period 
 
 Outpatient Inpatient LTC Rx Total 
Sample Size 
(N=2150) 
2150 205 43 79  
      
Age Category, 
Yrs 
Cost (SD)  Cost (SD)  Cost (SD)  Cost (SD)  Cost (SD) 
   21-31 $4,974.12 
(9,892.24) 
$66,159.67 
(95,155.66) 
$15,317.13 
(11,853.90) 
Not Reported $10,474.28 
(37,106.44) 
   32-42 $7,864.38 
(3,9064.30) 
$17,892.27 
(20,417.68) 
$16,991.25 
(21,832.58) 
Not Reported $9,145.42 
(40,010.68) 
   43-53 $8,797.30 
(19,197.17) 
$28,685.87 
(33,217.94) 
$15,042.08 
(12,966.71) 
$2,806.93 
(2,026.10) 
$12,077.99 
(27,448.39) 
   54-64 $7,300.63 
(12,791.84) 
$31,614.97 
(37,008.05) 
$12,025.32 
(11,092.65) 
$1,818.11 
(2,446.13) 
$10,883.88 
(22,306.49) 
P-Value 0.11 0.008* 0.85 0.49 0.57 
      
Gender Cost (SD)  Cost (SD)  Cost (SD)  Cost (SD)  Cost (SD) 
   Female $7,541.21 
(14,163.91) 
$33,308.78 
(42,980.62) 
$13,186.11 
(11,975.55) 
$2,034.04 
(2,416.60) 
$10,836.20 
(24,293.10) 
   Male $7,503.20 
(23,834.04) 
$31,198.63 
(43,043.54) 
$12,925.79 
(11,528.82) 
$1,663.2 (2,408.93) $11,051.17 
(31,208.87) 
      
P-Value 0.96 0.72 0.94 0.55 0.85 
      
 Subtypes Cost (SD)  Cost (SD)  Cost (SD)  Cost (SD)  Cost (SD) 
   MCI $7,850.47 
(16,656.54) 
$22,600.05 
(25,813.02) 
$10,531.03 
(14,357.78) 
$2,089 (1,939.95) $9,356.67 
(20,683.45) 
   AD $6,820.32 
(12,519.70) 
$50,025.70 
(61,189.08) 
Not Reported $1,876.48 
(2,512.71) 
$11,394.1 
(28,682.89) 
   LBD $11,971.27 
(17,851.8) 
$12,738.66 
(15,101.26) 
Not Reported Not Reported $15,445.58 
(20,000.46) 
   FTD $5,044.45 
(6,491.23) 
$13,860.80 
(9,184.72) 
Not Reported $1,452.37 
(1,045.95) 
$6,624.18 
(8,116.48) 
   VD $8,319.39 
(13,275.53) 
$23,353.46 
(18,996.03) 
$17,413.63 
(13,342.06) 
Not Reported $12,939.82 
(21,248.75) 
Dementia 
NOS 
$7,236.08 
(24,237.09) 
$34,452.6 
(49,169.75) 
$12,973.29 
(11,655.24) 
$1,736.52 
(2,824.20) 
$12,683.02 
(35,399.03) 
P-Value 0.82 0.06 0.91 0.94 0.15 
      
Geography Cost (SD)  Cost (SD)  Cost (SD)  Cost (SD)  Cost (SD) 
   Northeast $6285.54 
(10,180.29) 
$39,293.52 
(49,094.29) 
$18,880.99 
(11,826.98) 
$1,209.55 
(1,473.27) 
$10,292.17 
(24,023.40) 
   South $7,495.41 
(14,910.14) 
$22,526.86 
(26,187.76) 
$10,804.56 
(10,161.16) 
$2,101.79 
(2,842.71) 
$9,812.65 
(20,771.89) 
   Midwest $9,094.66 
(31,278.94) 
$38,811.54 
(44,959.15) 
$13,396.36 
(12,527.94) 
$2,016.21 (2661.29) $15,081.88 
(40,509.44) 
   West $6,880.73 
(16,168.75) 
$48,335.62 
(74,695.18) 
$3,803.4 
(5,131.11) 
$1,428.98 
(1,273.62) 
$9,531.14 
(24,479.61) 
P-value 0.18 0.01* 0.51 0.68 0.05 
      
Comorbidity Cost (SD)  Cost (SD)  Cost (SD)  Cost (SD)  Cost (SD) 
   No 
Comorbidity 
$2,469.39 
(3,652.19) 
$17,426.28 
(2,0791.91) 
Not Reported $1,371.4 (1995.98) $2,902.92  
(5777.2) 
   1 $8,819.62 
(24,938.58) 
$24,803 
(26,449.14) 
$11,076.75 
(12,732.15) 
$1,942.41 
(2,154.94) 
$13,128.66 
(35,275.14) 
   2 or more $9,726.33 
(20,327.32) 
$42,982.79 
(56,427.07) 
$15,128.21 
(10,517.08) 
$2,893.96 
(4,254.73) 
$14,232.13 
(24,189.9) 
P-Value <0.0001* 0.02* 0.43 0.01* <0.0001* 
      
* p < 0.05           
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Table 6. Generalized Linear Model Predictors of Total Direct Costs 
 
 Co-efficient Standard 
Error (SE) 
95% Confidence Interval P-value Marginal 
Effect¹ 
GLM Parameters      
Age Category Yrs, 
(ref 21-31) 
          
32-42 0.0062 0.1367 (-0.2168, 0.2742) 0.9636  
43-53 0.3272 0.1141 (0.1036, 0.5507) 0.0041* 38.7 
54-64 0.2063 0.1121 (-0.0134, 0.426) 0.0657  
Region  
(ref, South) 
          
Midwest 0.5116 0.0742 (0.3662, 0.657) <0.0001* 66.7 
Northeast 0.0478 0.0872 (-0.1232, 0.2188) 0.5838  
West -0.0126 0.0869 (-0.1828, 0.1576) 0.8845  
Comorbidity  
(ref, Comorbidity 
Absent) 
          
Congestive Heart 
Failure (CHF) 
2.036 0.1947 (1.6501, 2.4133) <0.0001* 664.1 
Hypertension (HTN) 
 
0.4854 0.0648 (0.3585, 0.3124) <0.0001* 62.4 
Cardiac Arrhythmias 
(CARDARR) 
1.2906 0.0927 (1.1088, 1.4724) <0.0001* 263.5 
Psychoses (PSYCH) 0.4839 0.2226 (0.0477, 0.9201) 0.029* 62.2 
Chronic Pulmonary 
Disease 
(CHRNLUNG) 
0.6001 0.1115 (0.3816, 0.8185) <0.0001* 82.2 
Rheumatoid Arthritis 
(ARTH) 
0.6312 0.2354 (0.1698, 1.0926) 0.007* 87.8 
Deficiency Anemia 
(ANEMDEFF) 
0.7002 0.1453 (0.4153, 0.985) <0.0001* 101.4 
Coagulopathy 
(COAG) 
0.916 0.3266 (0.2758, 1.5563) 0.0005* 148.5 
Pulmonary 
Circulations 
(PULMCIRC) 
1.4306 0.231 (0.9779, 1.8833) <0.0001* 318.1 
Peripheral Vascular 
Disorders 
(PERIVASC) 
0.8136 0.2578 (0.3083, 1.319) 0.0016* 125.6 
Valvular Disease 
(VALVE) 
0.9391 0.1544 (0.6364, 1.2418) <0.0001* 155.7 
Fluid and Electrolyte 
Disorders (LYTES) 
1.445 0.2084 (1.0365, 1.8534) <0.0001* 324.1 
1 - Marginal Effect represents the % 
increase in total cost when variable was 
present 
* p<0.05 
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Table 7. Mean Cost, $, Comparison between the Predictors of Total Mean Cost 
versus Mean Cost of Reference Variable, during a 12-month Time Period 
 
 Mean Cost, $ (reference) vs Mean Cost, $ (predictor) 95% Confidence 
Interval (predictor) 
Sample Size 
(N=2,150) 
Significant 
Predictors* 
   
Age Category, Yrs 
(ref 21-31) 
    
32-42* $9,145 (SD=$28,014) vs $9,338 (SD=40,010) ($8,446, $12,945) N=250 
43-53 $10,474 (SD=$37,106) vs $12,078 (SD=$27,448) ($9,704, $14,451) N=516 
54-64 $10,883 (SD=$35,225) vs 11,544 (SD=$25,389) ($9,328, $13,784) N=1198 
Region  
(ref, South) 
    
Midwest* $9,812 (SD=$20,771) vs $15,081 (SD=$40,509) ($11,303, $18,860) N=444 
Northeast $9,474 (SD=$19,225) vs $10,292 (SD=24,023) ($9,105, $15,226) N=358 
West $8,755 (SD=$23,555) vs $9,531 (SD=$15,331) ($8,066, $15,116) N=354 
Comorbidity  
(ref, Comorbidity 
Absent) 
    
Congestive Heart 
Failure (CHF)* 
$10,061 (SD=$25,730) vs $53,609 (SD=$62,528) ($34,365 , $72,825) N=43 
Hypertension (HTN)* $10,062 (SD=$28,724) vs $13,154 (SD=$24,426) ($11,204 , $15,105) N=605 
Cardiac Arrhythmias 
(CARDARR)* 
$9,410 (SD=$25,927) vs $24,284 (SD=$36,891) ($19,382 , $29,186) N=220 
Psychoses (PSYCH)* $10,823 (SD=$27,514) vs $17,929 (SD=$33,012) ($6,224 , $29,635) N=33 
Chronic Pulmonary 
Disease 
(CHRNLUNG)* 
$10,788 (SD=28,177) vs $13,177 (SD=17,309) ($10,263 , $16,091) N=138 
Rheumatoid Arthritis 
(ARTH)* 
$10,924 (SD=$27,754) vs $11,570 (SD=$13,418) ($6,446 , $16,674) N=29 
Deficiency Anemia 
(ANEMDEFF)* 
$10,710 (SD=$27,079) vs $16,620 (SD=$38,622) ($8,080 , $25,160) N=81 
Coagulopathy 
(COAG)* 
$10,894 (SD=$27,624) vs $16,429 (SD=$26,042) ($2,007 , $30,851) N=15 
Pulmonary 
Circulations 
(PULMCIRC)* 
$10,646 (SD=$27,112) vs $31,146 (SD=$39,171) ($16,519 , $45,772) N=30 
Peripheral Vascular 
Disorders 
(PERIVASC)* 
$10,771.39 (SD=$27,440) vs $25,238 (SD=$38,117) ($9,142 , $41,333) N=24 
Valvular Disease 
(VALVE)* 
$10,596 (SD=$27,546) vs $21,078 (SD=$28,749) ($14,172 , $27,985) N=69 
Fluid and Electrolyte 
Disorders (LYTES)* 
$10,523 (SD=$26,204) vs $32,511 (SD=$66,268) ($11,318 , $53,705) N=40 
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Figure 2. Cost of Predicators, in dollars, Compared to Overall Total Mean Cost, 
during a 12-month Time Period 
 
 
ARTH – Rheumatoid Arthritis 
AgeCat3 – 43-53 years old 
CHRNLUNG – Chronic Pulmonary Disease 
HTN – Hypertension 
Midwest – Region in U.S. 
COAG – Coagulopathy 
ANEMDEFF – Deficiency Anemia 
PSYCH – Psychosis 
VALVE – Valvular Disease 
CARDARR – Cardiac Arrhythmias* 
PERIVASC – Peripheral Vascular Disorder* 
PULMCIRC – Pulmonary Circulations* 
LYTES – Fluid and Electrolytes Disorders* 
CHF – Congestive Heart Failure* 
* Predictors that have a mean cost statistically significantly different than the total mean cost 
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APPENDIX A. International Classification of Disease 9th [ICD-9] Edition medical 
codes - Agency for Healthcare Research and Quality (AHRQ), using the Clinical 
Classification Software (CCS) from the Healthcare Cost and Utilization Project 
(HCUP) 
 
Alzheimer’s disease: 331.0      
Frontotemporal Dementia: 331.19     
Dementia with Lewy Body: 331.82     
Mild Cognitive Impairment: 331.83     
Vascular Dementia, Uncomplicated: 
290.40 
    
Vascular Dementia, with Delirium: 
290.41 
    
Vascular Dementia, with Delusion: 
290.42 
    
Vascular Dementia, with Depressed Mood: 
290.43 
   
Senile Dementia, Uncomplicated: 
290.0 
    
Senile Dementia, with Delusional Features: 
290.20 
   
Senile Dementia, with Depressive Features: 
290.21 
   
Senile Dementia, with Delirium: 290.3     
Pre-Senile Dementia, Uncomplicated: 290.10    
Pre-Senile Dementia, with Delirium: 290.11    
Pre-Senile Dementia, with Delusional Features: 290.12   
Pre-Senile Dementia, with Depressive Features: 290.13   
Dementia in Conditions Classified Elsewhere, without Behavioral Disturbance: 
294.10 
Dementia in Conditions Classified Elsewhere, with Behavioral Disturbance: 
294.11 
Dementia, Unspecified, without Behavioral Disturbance: 
294.20 
  
Dementia, Unspecified, with Behavioral Disturbance: 
294.21 
  
        
 
 
 
 
 
 
